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1. Riassunto 
L’Interleuchina (IL)-22, in gran parte prodotta dalle cellule T helper (Th) di tipo Th17 e Th22, è 
considerata una citochina chiave nella patogenesi della psoriasi poiché, responsabile della marcata 
iperplasia e dell’alterato differenziamento tipici della cute lesionale. In particolare, l’IL-22 induce la 
proliferazione dei cheratinociti, inibisce il loro differenziamento terminale e stimola la produzione di 
peptidi antimicrobici e chemochine. Signal transducer and activator of transcription (STAT) 3 è il 
mediatore principale del segnale indotto dall’IL-22 e la sua completa attivazione richiede la 
fosforilazione dei residui di tirosina (Tyr) 705 e serina (Ser) 727. La fosforilazione di STAT3 in Tyr705 
è inoltre proporzionale all’acetilazione del residuo di lisina (Lys) 685. I livelli di acetilazione di STAT3 
sono finemente regolati da processi di acetilazione e deacetilazione controllati, rispettivamente, dagli 
enzimi acetilasi p300 ed istone deacetilasi (HDAC). Dato che STAT3 appare altamente attivato 
nell’epidermide psoriasica, lo scopo del lavoro è di identificare molecole target capaci di contrastare 
l’attivazione di STAT3 mediata dall’IL-22 in cheratinociti umani. Per tale ragione è stato studiato 
l’effetto di Sirtuina (SIRT) 1, il rappresentante più caratterizzato della famiglia degli enzimi HDAC di 
classe III, nel controllo dell’attivazione di STAT3 e degli effetti biologici indotti dall’IL-22 in 
cheratinociti umani. E’ stato, infatti, precedentemente dimostrato che SIRT1 è in grado di deacetilare 
STAT3 nella Lys685 e, di conseguenza, di inibirne la fosforilazione in Tyr705 in cellule epatocitarie. E’ 
stato inoltre riportato che la sirtuina induce il differenziamento e blocca la proliferazione di cheratinociti 
umani. L’attività di ricerca ha permesso di dimostrare che la proteina SIRT1 è costitutivamente espressa 
in cellule primarie umane cheratinocitarie, dove essa contribuisce efficientemente alla deacetilazione di 
STAT3. Durante i processi d’infiammazione cutanea, caratterizzati dalla presenza concomitante 
dell’Interferone (IFN)-γ e dell’IL-22, l’IFN-γ riduce l’espressione di SIRT1, consentendo così all’IL-22 
di attivare STAT3. La riduzione dei livelli di SIRT1 determina, infatti, l’accumulo di STAT3 acetilato 
in Lys685 e favorisce così la fosforilazione di STAT3 in Tyr705 e le risposte dei cheratinociti all’IL-22. 
SIRT1 modula negativamente il Proliferating cellular nuclear antigen (PCNA), la ciclina D1 ed il 
phospho-Retinoblastoma (pRB), molecole indotte dall’IL-22 attraverso STAT3 e che giocano un ruolo 
fondamentale nella proliferazione cellulare. Inoltre, la sirtuina aumentando i livelli di cheratina (KRT)1, 
contrasta gli effetti anti-differenziativi esercitati dall’IL-22 in cheratinociti. Nelle lesioni psoriasiche, 
l’inibizione di SIRT1 potrebbe essere responsabile della forte attivazione di STAT3 e, quindi, delle 
risposte esagerate dei cheratinociti all’IL-22 e ad altre citochine pro-infiammatorie che segnalano 
attraverso STAT3 (IL-6 e oncostatina M). Un’altra molecola potenzialmente capace di controllare le 
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cascate molecolari e gli effetti biologici indotti dall’IL-22 in cheratinociti umani è il Suppressor of 
cytokine signalling (SOCS) 3. In cellule epatocitarie, infatti, l’aumento dell’espressione di SOCS3 
riduce l’attivazione di STAT3 mediata dall’IL-22. Tale studio ha permesso di dimostrare che SOCS3 è 
l’unico membro della famiglia dei SOCS ad essere indotto dall’IL-22 in cheratinociti umani. Anche se i 
livelli di SOCS1 non sono modulati dall’IL-22, la sua aumentata espressione in cheratinociti trasfettati 
stabilmente, inibisce le fosforilazioni di STAT3 in Tyr705 e Ser727 mediate dall’IL-22 in modo simile 
ai cloni SOCS3. Parallelamente, la trasfezione transiente dei cheratinociti con plasmidi per SOCS1 e 
SOCS3 riduce l’attività trascrizionale di STAT3 dipendente dall’IL-22. Viceversa, SOCS2 non è 
coinvolto nella regolazione dell’attivazione di STAT3. Conseguentemente all’inattivazione di STAT3, 
cheratinociti che esprimono alti livelli di SOCS1 e SOCS3 proliferano di meno dopo trattamento con IL-
22 rispetto alle cellule MOCK. Al contrario, l’effetto mitogenico dell’IL-22 è potenziato in cheratinociti 
che non esprimono il SOCS3. Inoltre, SOCS3 è in grado di ridurre l’espressione di geni pro-
infiammatori e di opporsi al de-differenziamento cheratinocitario dipendente dall’IL-22. Gli effetti 
inibitori di SOCS3 sull’attivazione di STAT3 dipendente dall’IL-22 sono esercitati dalla sua regione 
KIR (Kinase Inhibitory Region). L’uso di attivatori di SIRT1 o di molecole che mimano la regione KIR 
del SOCS3, in grado quindi di ridurre la fosforilazione di STAT3 in Tyr705 in cheratinociti epidermici, 
potrebbe essere utile per la cura della psoriasi, ma anche di altre patologie cutanee caratterizzate da 
un’aberrante attivazione di STAT3. 
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2. Abstract 
Interleukin (IL)-22 is a cytokine mainly released by T helper (Th) 17 and Th22 lymphocytes having a 
pathogenetic role in psoriasis. In this skin disorder, IL-22 is responsible for the altered proliferative and 
differentiative processes observed in the epidermis, and induces inflammatory molecules in 
keratinocytes. Signal transducer and activator of transcription (STAT) 3 is the principal mediator of IL-
22 signaling and its complete activation requires the phosphorylation in tyrosine (Tyr) 705 and in serine 
(Ser) 727 residues. Moreover, STAT3 phosphorylation in Tyr705 is proportional to the acetylation in 
lysine (Lys) 685 residue. STAT3 acetylation is tightly regulated by the acetylation and deacetylation 
processes, which are controlled by p300 acetylase and histone deacetylase enzymes (HDAC), 
respectively. Due to the aberrant STAT3 activation in psoriatic epidermis, the aim of this study was to 
identify the target molecules able to inhibit the IL-22-triggered STAT3 phosphorylation and down-
stream effects in human keratinocytes. For this purpose the role of Sirtuin (SIRT) 1, the most 
characterized Class III HDAC family member, has been studied in the control of IL-22-dependent 
signaling in keratinocytes. Indeed, it has previously demonstrated that SIRT1 is able to deacetylate 
STAT3 in Lys685 residue and, consequently, to inhibit STAT3 phosphorylation in Tyr705 in hepatocyte 
cells. Moreover, it was reported that the sirtuin is able to induce the differentiation and inhibit the 
proliferation of human keratinocytes. The research activity allowed us to demonstrate that SIRT1 is 
constitutively expressed by keratinocytes and that it efficiently contributes to STAT3 deacetylation in 
these cells. During inflammatory skin processes characterized by a concomitant presence of Interferon 
(IFN)-γ and IL-22, IFN-γ strongly down-regulates the keratinocyte expression of SIRT1 and IL-22 
activates STAT3. In fact, SIRT1 decrement determines an accumulation of STAT3 acetylated in 
Lys685, thus favoring STAT3 phosphorylation in Tyr705 and keratinocyte responses to IL-22. SIRT1 
negatively modulates the Proliferating cellular nuclear antigen (PCNA), cyclin D1 and phospho-
Retinoblastoma (pRB), that is STAT3-dependent and IL-22-induced molecules and play a fundamental 
role in cellular proliferation. In addition, the sirtuin, by enhancing the level of keratin (KRT) 1, counter-
acts the IL-22-triggered de-differentiate effect in keratinocytes. In psoriatic lesions, SIRT1 inhibition 
could be responsible for the strong activation of STAT3 and, thus, for the exaggerated responses of 
epidermal keratinocytes to IL-22 and other pro-inflammatory cytokines signaling through STAT3 (i.e., 
IL-6 and oncostatin M). Suppressor of cytokine signalling (SOCS) 3 represents another possible 
candidate able to control the IL-22-derived molecular cascades and the biological effects in 
keratinocytes. Indeed, in hepatocyte cells, the enhanced expression of SOCS3 level reduces the IL-22-
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dependent STAT3 activation. In this study it has been demonstrated that SOCS3 is the only SOCS 
family member induced by IL-22 in human keratinocytes. Interestingly, even though SOCS1 was not 
up-regulated by IL-22, its over-expression in stably trasfected keratinocytes potently inhibited the IL-
22-induced Tyr705 and Ser727 phosphorylations of STAT3, likewise to what observed in SOCS3 
clones. Consistently, transient transfection of keratinocytes with SOCS1 or SOCS3 plasmids markedly 
reduced the IL-22-induced STAT3 transcriptional activity. In contrast, stable or transient SOCS2 over-
expression in keratinocytes had no effects on STAT3 activation by IL-22. As consequence of STAT3 
inactivation, the IL-22-induced proliferation was impaired in SOCS3 and SOCS1 clones compared to 
mock-trasfected keratinocytes. Vice versa, the mitogenic effect exerted by IL-22 on keratinocytes 
depleted of SOCS3 was more pronounced. Moreover, SOCS3 reduces the expression of IL-22-
dependent pro-inflammatory genes and opposes to the de-differentiative effect of the cytokine in 
keratinocytes. The SOCS3 inhibitory effect on the IL-22-induced STAT3 activation is executed by 
SOCS3 KIR (kinase inhibitory region) domain. Therefore, the use of SIRT1 activators or molecules able 
to mimic SOCS3-KIR region, able to reduce the STAT3 Tyr705 phosphorylation in epidermal 
keratinocytes, could be therapeutically useful for the treatment of psoriasis as well as other skin diseases 
characterized by an aberrant STAT3 activation. 
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3. Introduction 
3.1 Clinical and histologic features of psoriasis 
Psoriasis is a chronic recurrent inflammatory skin disease estimated to affect 2–3% of the general 
population [1]. Within the spectrum of cutaneous manifestations of psoriasis, different expressions are 
seen. Individual lesions may vary in size from pinpoint to large plaques, or even erythroderma [2]. More 
specifically, the clinical spectrum of psoriasis includes the plaque, guttate, small plaque, inverse, 
erythrodermic, and pustular variants. The most common and well-recognized morphologic presentation 
of psoriasis is that of the plaque type. The disease usually is characterized by the formation of demarked 
erythematous plaques with large scaling. The scales are a result of a hyperproliferative epidermis with 
premature maturation of keratinocytes and incomplete cornification with retention of nuclei in the 
stratum corneum (parakeratosis). The mitotic rate of the basal keratinocytes is increased as compared 
with that in normal skin. As a result, the epidermis is thickened (acanthosis), with elongated rete ridges 
that form fingerlike protrusions into the dermis (Fig. 3.1). The granular layer of the epidermis, the 
starting site of terminal keratinocyte differentiation, is strongly reduced or missing [2]. The epidermis 
becomes infiltrated by neutrophils and activated CD8+ T lymphocytes. Within the dermis, an 
inflammatory infiltrate composed mainly of CD3+ T lymphocytes, dendritic cells (DC), macrophages, 
mast cells and neutrophils is observed [1]. Elongated and dilated blood vessels in the dermal papillae 
represent a further histological hallmark of psoriatic skin lesions. 
 
3.2 Pathogenetic mechanisms operating in psoriasis 
Even though successful treatment regimens for the therapy of psoriasis have been established for a long 
time, the primary pathogenetic mechanism and the cell type(s) involved in the onset of the disease are 
still under debate. Psoriasis is classically responsive to trigger factors that can induce psoriasis de novo 
or exacerbate skin lesions. Trigger factors range from nonspecific stimuli such as skin trauma to more 
specific triggers such as pathogens (i. e. streptococci) or drugs (i. e. lithium, interferon (IFN)-α) [1]. All 
these factors generate a pathogenetic cascade culminating in the expansion of lesional and/or circulating 
T cells in the psoriatic skin. T-lymphocyte infiltrate present in active psoriatic skin establishes a 
cytokine milieu that dictates specific and pathogenetic gene signatures in resident skin cells [3]. Thus, 
cytokine-activated keratinocytes overexpress a number of inflammatory mediators that aberrantly 
amplify and sustain the psoriasiform tissue reactions [4]. Importantly, intrinsic defects and/or alterations 
of keratinocytes in their immune response to pro-inflammatory cytokines are fundamental for the 
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induction of psoriatic processes, as demonstrated in genetically-manipulated mouse systems. In 
particular, transgenic animals that overexpress the transcription factor STAT3 [5] or that lack the 
inhibitor of NF-κB kinase-2 (IKK-2) [6] in the epidermis developed skin lesions that closely resembled 
human psoriasis. Similarly, the abrogation of JunB in keratinocytes triggered in mice a skin phenotype 
with the histological hallmarks of psoriasis, including marked hyperplasia of the epidermis accompanied 
by a dense dermal infiltrate of inflammatory cells [7]. The hyperplasia observed in these mice could, in 
part, depend on the overexpression of S100A8 and S100A9, two antimicrobial peptides that have 
chemotactic activity and a well-known role in keratinocyte maturation and proliferation processes. The 
development of psoriatic lesions in mice overexpressing STAT3 in the epidermis depends on the 
presence of activated T cells, whereas the inflammatory responses occurring in the skin of IKK2-
transgenic mice are mediated by TNF-α. Therefore, it is clear that an intrinsically dysregulated 
interrelation between keratinocytes and cells of both the innate and acquired immune response is a key 
factor in the pathogenesis of psoriasis. Based on the analysis of infiltrating T cell types, their secreted 
products, and genetic signatures present in lesional skin, psoriasis has been considered for many years as 
a type-1 tissue reaction with a prominent role for T cell-derived interferon (IFN)-γ [8]. However, other 
cytokines and T-cell subsets have been identified as fundamental players during inflammatory responses 
in psoriasis. They include IL-21-relasing T cells, which have been shown to regulate keratinocyte 
proliferation in psoriatic skin, Th17 cells and the recently identified IL-22-producing type Th22 cells [9-
11]. Both IL-17 and IL-22 belong to a class of cytokines with predominant effects on epithelial cells. 
Keratinocytes, in fact, are strongly influenced by IL-17 and in response to this cytokine up-regulate 
chemokines and immune-modulatory molecules [12]. A functional role of Th17 cells in psoriasis is 
suggested by their reduction during successful anti-TNF-α treatment [13]. IL-22 also acts 
pathogenetically in psoriatic skin, as it regulates proliferative processes and the expression of innate 
immunity molecules in psoriatic keratinocytes (see below) [14]. 
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                                   Figure 3.2: Hematoxilyn-eosin staining of a plaque variant of psoriatic skin [2] 
 
 
3.3 IL-22 and its pathogenetic role in psoriasis  
IL-22, together with IL-19, IL-20, IL-24, and IL-26, belongs to a family of cytokines structurally related 
to IL-10 [15]. IL-22 is mainly produced by mast cells, natural killer (NK) cells and Th22 cells [11, 14]. 
IL-22 acts through a heterodimeric receptor containing the IL-10 receptor (R) 2 and IL-22R1 chains [16] 
(Fig. 3.3). IL-10R2 is widely expressed on immune cells, whereas IL-22R1 expression is restricted to 
non-hematopoietic cells, such as epidermal keratinocytes and epithelial cells of the gastrointestinal tract 
and the lung [17, 18]. Upon binding to its R1 chain, IL-22 induces a conformational change that enables 
IL-10R2 to interact with the newly formed ligand-receptor complexes. This, in turn, activates Janus 
kinase (JAK) 1 and tyrosine kinase (Tyk) 2, leading to the Tyr705 phosphorylation of STAT3 [19]. The 
tyrosine phosphorylation of STAT3 in the cytoplasm leads to its dimerization, translocation into the 
nucleus, and DNA binding. Therefore, STAT3 phosphorylation in Ser727 residue is necessary to 
maximize STAT3 transcriptional activity [20]. IL-22 was also found to activate the Extracellular-signal-
regulated kinase (ERK), c-Jun N-terminal kinases (JNK), and p38 Mitogen-activated protein kinase 
(MAPK) in the rat hepatoma cell line H4IIE [19]. In addition, IL-22 up-regulates the mRNA expression 
of suppressor of cytokine signalling (SOCS) 3, which abrogates IL-22-induced STAT signaling in 
hepatic cells through a classical negative feed-back loop [21]. A soluble IL-22-binding protein, IL-
22RA2, encoded by a distinct gene has been identified. This soluble receptor, which has 34% amino 
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acid identity to the extracellular domain of the IL-22RA1, binds IL-22 and antagonizes its functional 
activities [22] (Fig. 3.3).  
 
 
 
 
 
 
 
 
 
 
 
                              Figure 3.3: Model of the IL-22R complex and signal transduction.  
 
Wolk et al. have demonstrated that IL-22 mRNA is massively elevated in psoriatic skin lesions [23]. 
The increase of the IL-22 mRNA level in lesional skin is much greater than that of the cytokines IFN-γ 
and IL-1β, at that time viewed as pathogenetically relevant for this disease [18]. Further analyses of 
samples of psoriasis patients revealed that the local expression of IL-22 is associated with high IL-22 
blood plasma levels, whereas again the plasma levels of IFN-γ, IL-17 and IL-1β were only minimally 
elevated [24]. A correlation analysis demonstrated a clear positive relationship between the IL-22 blood 
plasma levels and the severity of the disease [24]. After anti-psoriatic therapy a marked reduction of 
both the cutaneous IL-22 mRNA expression and the IL-22 blood plasma level was seen. In keratinocytes 
IL-22 regulates a number of genes which can be divided into three functional categories: antimicrobial, 
differentiation-associated, and mobility regulating genes [24]. The antimicrobial peptides induced by IL-
22 in keratinocytes include β-defensin 2 and 3, and the S100 proteins S100A7, S100A8, and S100A9. In 
addition, IL-22 inhibits the terminal differentiation of keratinocytes, which is a prerequisite for the 
normal formation of corneocytes of the stratum corneum of the skin and for physiologic desquamation. 
In particular, the cytokine reduces the expression of genes essential for the keratinocyte differentiation 
in the stratum spinosum of the epidermis, such as profillagrin, cheratin (KRT) 1, KRT10, desmoccollin-
1 and kallikrein-7 [24]. IL-22 promotes the production of cellular mobility associated molecules matrix 
metalloproteinases (MMP) 1 and 3 and inhibits annexin A9 production. IL-22 induces the production of 
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chemokines recruiting neutrophilic granulocytes as a prerequisite for migration of these cells into the 
skin. Moreover, in human skin equivalents and human keratinocyte cultures, IL-22 enhances IL-20 
mRNA expression, protein expression, and secretion [25]. IL-20, in turn, amplifies and/or prolongs the 
IL-22 inhibitory action on keratinocyte differentiation that leads to the characteristic epidermal changes 
observed in psoriatic epidermis, such as the decrease in the granular cell layer (hypogranulosis) and an 
increase in epidermis thickness (acanthosis) [26, 27]. Interestingly, the IL-22-induced inhibition of the 
terminal keratinocyte differentiation does not seem to be associated with an expression change of anti- 
or pro-apoptotic proteins. However, it coincided with the induction of STAT3 expression that was 
necessary for this IL-22 effect [26]. These facts, together with the high IL-22 expression levels in 
psoriatic plaques and in the blood of psoriasis patients, suggest that IL-22 plays a major role in the 
keratinocyte alterations in psoriasis [18, 24]. This postulated role of IL-22 in the pathogenesis of 
psoriasis was further supported by three studies in mice: Zheng et al. found that repeated cutaneous 
application of IL-23 induced acanthosis in mice in an IL-22-dependent way [28]. The Fouser group 
investigated a psoriasis-like disease model in mice, which is induced by the transfer of T cells to 
pathogen-free scid/scid mice [29]. In this model, neutralization of IL-22 reduced acanthosis, 
inflammatory infiltrates, and expression of some cytokines. In the third study, Wolk et al. demonstrated 
that transgenic overexpression of IL-22 in mice resulted in neonatal mortality and psoriasis-like skin 
alterations including epidermal acanthosis and hypogranularity [30]. In addition, STAT3 is activated in 
lesional keratinocytes from psoriatic patients [31]. This up-regulation of STAT3 activation in psoriasis 
does not appear to be a secondary outcome of epidermal hyperplasia, because lesions from non-psoriatic 
inflammatory skin diseases with characteristic acanthosis show a STAT3 staining pattern similar to 
normal epidermis. Moreover, K5.Stat3C transgenic mice, in which STAT3 is constitutively active in 
keratinocytes, develop psoriasiform lesions after wounding stimuli or topical treatment with the tumor 
promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), which strongly suggests that STAT3 activation 
is required for the development of psoriasis [5].  Expectedly, a topical pre-treatment of K5.Stat3C mice 
with STAT3 decoy oligonucleotides abrogates the de novo generation of tape stripping induced psoriatic 
lesions with less T cell infiltrates [32]. In addition, Miyoshi et al. have recently reported that topical 
treatment with STA-21, an antibiotic which blocks STAT3 dimerization and DNA binding, not only 
inhibits the development of psoriasiform lesions in K5.Stat3C mice, but also ameliorates psoriatic 
lesions in six of the eight psoriasis patients, suggesting that an inhibition of STAT3 activation could be a 
reliable therapy for psoriasis [33]. 
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3.4 Modulation of STAT3 activation 
3.4.1 Role of SIRT1 
Post-translational modifications of many if not all proteins critically regulate their biological functions. 
It is now well accepted that these modifications are required to face challenges and stress from the 
environment, to trigger a variety of processes ranging from cell proliferation, differentiation, and 
autophagy to apoptosis [34]. These modifications, when not properly regulated, also contribute to 
multiple pathologies such as cancer and auto-immune diseases. Therefore, several disease-related 
research programs are currently ongoing in order to better understand the pathways that involve these 
post-translational modifications and to subsequently define new therapeutic targets. Protein 
phosphorylation is the most widely studied modification but early evidence suggested that many other 
protein modifications such as methylation, ubiquitination, sumoylation and lysine acetylation also occur 
in vivo [35]. Lysine acetylation, defined as the addition of an acetyl moiety to the ε-amino group of a 
lysine residue, has been linked for many years to gene transcription [34]. Interestingly, it has been 
reported that STAT3 acetylation in Lys685 residue is essential for the phosphorylation of STAT3 in 
Tyr705 in hepatic cells [35]. Acetylation of STAT3 relies on a tight balance between acetylation and 
deacetylation performed primarily by p300 acetylase and histone deacetylase enzymes (HDAC), 
respectively [35]. There are two protein families with HDAC activity: Class III NAD-dependent HDAC 
(sirtuins) and the classical HDAC family (Classes I and II). Class I and II use a zinc as cofactor and are 
inhibited by Tricostatin A (TSA), whereas sirtuins aren’t sensible to TSA and use NAD+ to convert 
acetylated protein substrates into deacetylated protein, nicotinamide and the acetyl ester metabolites 
(Fig. 3.4.1) [36, 37]. The human sirtuin family is made up of seven members, SIRT1-7, with each 
having distinct cellular targets and cellular localizations (Table 3.4.1). Most sirtuins (SIRT1, -3 and -5) 
catalyze reactions of deacetylation, whereas SIRT4 and SIRT6 are mono-ADP-ribosyl transferases with 
no deacetylase activity. Acetylated histones H1, H3, and H4 are known to be physiological substrates 
for the sirtuins, and lysine 16 in histone H4 appears to be the most critical residue for sirtuin mediated 
transcriptional silencing. However, SIRT1-3 also target non-histone proteins, including various 
transcription factors [38]. SIRT1 is the best characterized sirtuin member and it is localized to either the 
nucleus or cytoplasm depending on tissue and cell type [38]. 
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                                             Figure 3.4.1: Reaction of deacetylation catalysed by sirtuins. 
 
It deacetylates several transcription factors involved in the regulation of cellular proliferation, apoptosis, 
differentiation, metabolism and inflammation [38]. Of note, SIRT1 counteracts STAT3 activation in 
different cell types [39-41].  In particular, SIRT1-mediated deacetylation of STAT3 in murine skeletal 
muscle cells determines the reduction of STAT3 binding to the p55α/p50α regulatory subunits of 
phosphoinositide 3-kinase (PI3K), thereby promoting PI3K signaling activation during insulin 
stimulation [40]. Moreover, the sirtuin decreases mitochondrial biogenesis and cellular respiration in 
murine embryonic fibroblasts, through the inhibition of STAT3 expression and serine phosphorylation 
[41]. Interestingly, SIRT1 plays an important role during keratinocyte proliferation and differentiation. 
In fact, it has been reported that SIRT1 induces the differentiative programs and inhibits the proliferative 
processes in human keratinocytes through the regulation of E2F1 transcriptional activity [42]. 
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                                                         Table 3.4.1: Sirtuin function and localization. 
 
These SIRT1-mediated effects are specific of keratinocytes and are not shared by other cell types, such 
as white adipocytes and myocytes, where SIRT1 overexpression counteracts differentiative processes 
[43, 44]. 
 
3.4.2 Role of SOCS proteins 
SOCS proteins and cytokine-inducible SRC homology 2 (SH2)-domain-containing proteins (CIS) 
comprise a family of intracellular proteins, several of which have been shown to regulate the responses 
of immune cells to cytokines [45]. There are eight members of the CIS–SOCS family (CIS and SOCS1-
7), each of which has a central SH2 domain, an amino-terminal domain of variable length and divergent 
sequence, and a carboxy-terminal 40-amino-acid module that is known as the SOCS box (Fig. 3.4.2.A). 
The SOCS box interacts with elongin B and elongin C, cullin-5 and RING-box-2 (RBX2), which 
recruits E2 ubiquitin transferase [45]. CIS–SOCS-family proteins, as well as other SOCS-box-
containing molecules, probably function as E3 ubiquitin ligases and mediate the degradation of proteins 
that are associated with these family members through their N-terminal regions. In addition to their 
ability to suppress signaling by ubiquitin-mediated degradation of the signaling complex, both SOCS1 
and SOCS3 can inhibit JAK tyrosine kinase activity directly through their kinase inhibitory region 
(KIR), which is proposed to function as a pseudosubstrate and is important for the suppression of 
cytokine signals (Fig. 3.4.2.A) [45]. 
 
 
  
Sirtuin Type of enzyme Subcellular localization 
SIRT1 Deacetylase Cytoplasm and nucleus 
SIRT2 Deacetylase Cytoplasm and nucleus 
SIRT3 Deacetylase and ADP-rybosiltransferase Mitochondria 
SIRT4 ADP-rybosiltransferase Mitochondria 
SIRT5 Deacetylase Mitochondria 
SIRT6 Deacetylase and ADP-rybosiltransferase Nucleus 
SIRT7 Deacetylase Nucleus 
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                                                  Figure 3.4.2.A: Schematic structure of the SOCS proteins. 
 
In general, the constitutive level of SOCS protein expression in cells is low, but SOCS protein 
expression is highly inducible, often in a transient manner, upon stimulation with cytokines both in vitro 
and in vivo (Fig. 3.4.2B, left scheme). SOCS-mediated down-regulation of cytokine-induced JAK-STAT 
signaling involves different mechanisms (Fig. 3.4.2B). Via its SH2 domain, SOCS1 binds directly to the 
JAK and inhibits kinase activity [46]. SOCS3 also inhibits JAK activity, but in contrast to SOCS1, this 
requires binding between the SH2 domain of SOCS3 and the phosphorylated receptor [47]. Finally, 
SOCS proteins can inhibit signaling by coupling of signaling proteins to degradation via the 
proteasomal machinery (Fig. 3.4.2B, right scheme) [45]. 
 
 
 
 
 
         
 
 
                                     Figure 3.4.2B: SOCS proteins inhibit cytokine signaling. 
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Induction of SOCS expression by various cytokines is STAT-dependent, and indeed, the promoter 
regions of the CIS [48], SOCS1, and SOCS3 genes [49] show functional STAT-binding elements. 
Cytokine-induced expression of SOCS1 and SOCS3 can be inhibited by STAT3 dominant negative 
mutants [49], while gene expression of CIS can be inhibited by STAT5 dominant negative mutants [50]. 
From evidence suggesting that forced expression of SOCS3 can inhibit IL-6-mediated STAT3 activation 
it was proposed that SOCS3, which is induced by STAT3 activation, can act as a negative-feedback 
regulator of STAT3. For instance, Socs3 gene therapy, using adenoviral-mediated gene delivery, 
suppresses the IL-6-induced and STAT3-mediated proliferation of cultured synovial fibroblasts as well 
as significantly reduced the onset and progression of experimental antigen- and collagen-induced 
arthritis in mice [51]. Moreover, the reduction of SOCS3 expression and the consequent increase of 
STAT3 activation contribute to the development of cancer in multiple neoplasias, including 
cholangiocarcinoma, hepatocellular carcinomas and breast and lung cancer [52]. In addition, cytokine- 
and growth factor-induced STAT3 activation is inhibited by SOCS3 in keratinocyte cells. In particular, 
the over-expression of SOCS3 in keratinocytes abrogates the Hepatocyte growth factor (HGF)-derived 
STAT3 activation and proliferative effects [53]. Furthermore, the keratinocyte-specific conditional 
ablation of SOCS3 in transgenic mice resulted in an aberrant STAT3 activation associated with 
keratinocyte hyperproliferation [54]. The role of SOCS3 molecules in the control of IL-22-mediated 
STAT3 activation in keratinocytes is yet unknown. Of note, IL-22 is able to upregulates the mRNA 
expression of SOCS3 in hepatic cells [55]. Moreover, SOCS3 overexpression abrogates IL-22-induced 
STAT3 activation preventing IL-22-induced liver cell regeneration. 
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4. Materials and Methods 
4.1 Tissue samples 
For immunohistochemistry, 4-mm punch biopsies were taken from lesional (LS) skin of adult patients 
with chronic plaque psoriasis and from normal skin of healthy subjects undergoing plastic surgery. For 
patients with psoriasis, a skin biopsy from non lesional (NLS) skin distant from the plaques was also 
taken. Keratinocyte cultures were established from 6-mm biopsies obtained from both involved and 
uninvolved skin of patients with psoriasis and from healthy control subjects. The study was approved by 
the Ethical Committee of the IDI-IRCCS (Rome, Italy). 
 
4.2 Keratinocyte cultures and treatments 
Primary cultures of human keratinocytes were obtained from skin biopsies, as previously described [56]. 
Keratinocyte cultures were grown in serum-free keratinocyte growth medium (KGM; Clonetics, 
Walkersville, MD, USA), for 3-5 days (at 60–80% confluence) before performing experiments. 
Stimulations with 50 ng/ml IL-22, 200 U/ml IFN-γ, 50 ng/ml TNF-α, or 50 ng/ml IL-17 (all from R&D 
Systems, Minneapolis, MN, USA) were performed in keratinocyte basal medium (KBM, Clonetics). 
Subconfluent cultures were also stimulated with supernatants from Th1 clones or RPMI medium diluted 
1:3 in KBM. Terminal differentiation of keratinocyte cultures was achieved by growing cells at 100% of 
confluence (t0) and, thus, keeping them in culture for another 4 days. Keratinocytes undergoing 
differentiation were also cultured in the presence of IL-22 and/or IFN-γ. The HaCaT human keratinocyte 
cell line was a gift from N. E. Fusenig (Deutsches Krebsforschungszentrum, Heidelberg, Germany) and 
was grown in Dulbecco modified Eagle medium (DMEM; Biochrom, Cambridge, UK) supplemented 
with 10% Fetalclone II serum (HyClone Laboratories, South Logan, UT, USA). CD4+ T-cell clones 
were obtained from peripheral blood of patients with psoriasis, as previously described [57]. Cells were 
periodically stimulated with 1% phytohemagglutinin (Invitrogen, Carlsbad, CA, USA), and were 
activated with plate-coated anti-CD3 and soluble anti-CD28 (both at 1 µg/ml). Clone supernatants were 
assayed for IFN-γ, TNF-α, IL-17, IL-22, and IL-4 content with a commercially available ELISA kit 
(R&D Systems). Clones were classified depending on their cytokine profile, and supernatants of Th1 
clones containing levels of IFN-γ > 20 ng/ml were used on keratinocyte cultures. 
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4.3 RNA isolation, polymerase chain reaction (PCR) and real-time PCR 
Total RNA was extracted using the TRIzol reagent (Invitrogen, Carlsbad, CA, USA). mRNA was 
reverse-transcribed into cDNA and analyzed by real-time PCR or PCR. The mRNA expression of all 
analyzed genes through real-time PCR procedure was evaluated in the ABI Prism SDS 7000 PCR 
instrument (Applied Biosystems, Branchburg, NJ, USA), using SYBR Green PCR reagents or Taqman 
PCR Master Mix. The forward and reverse primers employed were as follows: for CXCL8, 5'-
GCTGGCTTATCTTCACCATCATG-3 'and 5'-TTATTTTTTTTCAGTTAATTAACAGATGCT 
ATCAT-3'; for SOCS3, 5'-AAGGACGGAGACTTCGATTCG-3' and 5'-AAACTTGCTGTGGG 
TGACCAT-3'; for SOCS1, 5'-TTTTTCGCCCTTAGCGTGA-3' and 5'-AGCAGCTCGAAGAG 
GCAGTC-3'; for STAT3, 5'-GGCGTCACTTTCACTTGGGT-3' and 5'-CCACGGACTGGATCT 
GGGT-3; for STAT1, 5'-TTGCTTGGATCAGCTGCAGA-3' and 5'-GCTGCAGACTCTCCGC 
AACTA-3'; for SIRT1, 5'-GCTGGCCTAATAGAGTGGCAA-3' and 5'-CTCAGCGCCATGGAA 
AATG-3', for β-actin, 5'-CATCGAGCACGGCATCGTCA-3' and 5'-TAGCACAGCCTGGATA 
GCAAC-3'. The sequences of the primers and internal probe for HBD-2 mRNA have been previously 
described [58]. Primers for CXCL1 (Hs00236937), S100A7 (Hs00161488), CIS (Hs003203371), 
SOCS2 (Hs00919620), SOCS4 (Hs00328404), SOCS5 (Hs00367107), SOCS6 (Hs00377781), SOCS7 
(Hs00389987) and HPRT1 (Hs01003267) were provided by Applied Biosystems. The levels of gene 
expression were determined by normalizing to β-actin or HPRT1 mRNA expression. The values 
obtained from triplicate experiments were averaged, and data are presented as means ± sd. The mRNA 
expression of sirtuin members was analyzed by Semi-Quantitative PCR conducted in a Thermal Cycler 
(Applied Biosystems). The primer pairs’ specific for the family sirtuin members were as follows: SIRT1 
(GenBank NM_012238; oligonucleotide forward 405-428 bp, reverse 563-586 bp); SIRT2 (GenBank 
NM_012237; oligonucleotide forward 438–461 bp, reverse 699–722 bp); SIRT3 (GenBank 
NM_012239; oligonucleotide forward 290–313 bp, reverse 527–550 bp); SIRT4 (GenBank 
NM_012240; oligonucleotide forward 414–437 bp, reverse 565–588 bp); SIRT5 (GenBank 
NM_012241; oligonucleotide forward 365–388 bp, reverse 507–530 bp); SIRT6 (GenBank 
NM_016539; oligonucleotide forward 301–324 bp, reverse 487– 510 bp); SIRT7 (GenBank 
NM_016538; oligonucleotide forward 605–628 bp, reverse 849–872 bp). Amplification conditions 
were: denaturation 95uC, 30 sec; annealing 55uC, 1 min; extension 68uC,1 min. [a-32P]dATP was 
added to the reaction (0.04 mCi/ml); 32 cycles were performed to obtain sirtuin amplicons, whereas 24 
cycles were used for GAPDH amplicon. PCR products were separated on a 6% polyacrylamide gel and 
quantitatively analyzed in a Typhoon Trio imager system using the IMAGE QUANT version 5.0 
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software (GE Healthcare, Amersham, UK). PCR products were also separated on a 2% agarose gel, 
extracted from the gel with the Gel Extraction kit (Qiagen) and sequenced.  
 
4.4 Flow cytometry analysis 
Keratinocyte expression of membrane Intercellular Adhesion Molecule (ICAM)-1, Human Leukocyte 
Antigen (HLA)-DR, and Major Histocompatibility Complex (MHC) Class I was evaluated using 
fluorescein isothiocyanate-(FITC)-conjugated anti-CD54 (84H10, Immunotech, Marseille, France), anti-
HLA-DR (L243, BD Pharmingen, Franklin Lakes, NJ, USA), and anti-HLA-ABC (G46-2.6, BD 
Pharmingen) monoclonal antibodies (mAbs). In control samples, staining was performed using isotype-
matched control Abs. Cells were analyzed with a FACScan equipped with Cell Quest software (Becton 
Dickinson, Mountain View, CA). 
 
4.5 Western Blotting  
Total proteins were prepared by solubilizing cells in RIPA buffer (1% NP-40, 0.5% sodium 
dehoxycholate, and 0.1% SDS in PBS containing a mixture of protease and phosphatase inhibitors). 
Alternatively, cytosolic and nuclear extracts were prepared from cells grown in 75-mm flasks, which 
were lysed with 1 ml cold Buffer A (20 mM HEPES [pH 7.9], 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 
1.5 mM MgCl2, 0.2% NP-40, and 1 mM DTT plus protease and phosphatase inhibitors). After 
centrifugation, the supernatants containing cytoplasms were collected, whereas the pellets containing 
nuclei were resuspended in 0.4 ml cold Buffer B (20 mM HEPES [pH 7.9], 0.35 M NaCl, 10 mM KCl, 
1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl2, 10% glycerol, and 1 mM DTT plus protease and 
phosphatase inhibitors). After incubation at 4°C for 30 min, the suspensions were centrifuged at 14,000 
rpm for 10 min, and the supernatants collected and diluted 5-fold in Buffer C (20 mM HEPES [pH 7.9], 
60 mM NaCl, 10 mM KCl, 1 mM EDTA, 1 mM EGTA, 1.5 mM MgCl2, 5% glycerol, 0.05% NP-40, 
and 1 mM DTT plus protease and phosphatase inhibitors). The resulting samples were aliquoted and 
frozen at –80°C. Total, cytosolic, or nuclear proteins were subjected to SDS-PAGE, and transferred to 
polyvinylidene difluoride (PVDF) membranes (Amersham Pharmacia Biotech, Buckinghamshire, U.K.). 
The latter were blocked and probed with various primary Abs diluted in PBS containing 5% nonfat dried 
milk or 3% BSA. The primary Abs employed for the study were as follows: anti-PCNA (PC10), anti-
cyclin D1 (DCS-6), anti-phospho-RB (Ser795), anti-lamin A/C (346), anti-α-tubulin (B-7), anti-β-actin 
(C-11), anti-phospho-STAT3 (Ser727), anti-STAT3 (C-20), anti-phospho-STAT1 (Tyr701), anti-
STAT1 (E-23), antiphospho-ERK1/2 (E-4), anti-ERK1/2 (C16), and anti-SIRT1 (H-300), and HRP-
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conjugated anti-c-myc (9E10) all provided by Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-
KRT1, anti-KRT5, anti-KRT14, and anti-loricrin Abs were from Covance (Emeryville, CA, USA), 
whereas anti-phospho-STAT3 (Tyr705) and anti-acetyl-STAT3 (K685) were from Cell Signaling 
Technology (Danvers, MA, USA). Anti-FLAG (M2; Sigma-Aldrich, Saint Louis, MO, USA) and anti-
SIRT7 (RB1973; Abgent, San Diego, CA, USA) were also used. Western blotting filters were properly 
developed with anti-mouse, anti-goat, or anti-rabbit Ig Abs conjugated to HRP using the ECL-plus 
detection system (Amersham), or, otherwise, the SuperSignal West Femto kit (Pierce, Rockford, IL, 
USA). 
 
4.6 Transient RNA interference 
STAT3, SIRT1, SIRT2, SIRT5, SIRT7 and SOCS3 were knocked down by using a pool of 4 small short 
interfering (si)RNAs (ON-TARGETplus SMARTpool, Dharmacon RNA Technology, Lafayette, CO, 
USA). In parallel, a pool of 4 Non-targeting siRNAs was used as negative control. Primary cultures 
were transfected with STAT3, SIRT1, SIRT2, SIRT5, SIRT7, SOCS3 or irrelevant siRNA at 50 nM 
final concentration using Interferin reagent (Polyplus Transfection, New York, NY, USA). After 2 d of 
mRNA silencing, keratinocytes were treated with different stimuli.  
 
4.7 Luciferase assay, transient and permanent transfections 
Cultured keratinocytes grown in 12-well plates were transiently transfected with the STAT3-responsive 
plasmid pLucTKS3 (a generous gift of Prof. J. Turkson, University of Central Florida, Orlando, FL, 
USA) by using Fugene reagent (Promega, Madison, WI, USA). After transfection, cells were 8 hours 
stimulated with IL-22, and Firefly luciferase activity was measured using the Dual-Glo Luciferase 
Assay System (Promega). pRL-null plasmid encoding the Renilla luciferase was included in each 
transfection. Primary keratinocytes were transiently transfected with pcDNA3-hSIRT1-FLAG (kindly 
provided by Prof. F. Ishikawa, Kyoto University, Kyoto, Japan), or pcDNA-myc/SOCS1-2-3 (a 
generous gift of Dr. A. Yoshimura, Kyushu University, Fukuoka, Japan) and pLucTKS3 luciferase was 
measured using the pcDNA3.1 plasmid as negative control. In addition, a panel of plasmids expressing 
wild-type or mutated SOCS3 were transiently co-transfected in keratinocytes with the pTKS3Luc 
plasmid, and luciferase activity was evaluated after IL-22 treatment. SOCS3 mutated plasmids dN25 
(KIR-deleted), dN36 (KIR- and part of ESS-deleted), L22D (single-mutation in KIR), R71E (single-
mutation in SH2) and dC40 (SOCS box-deleted) were a generous gift of Prof. Yoshimura. HaCaT cells 
were permanently transfected with pcDNA-myc/SOCS1-2-3 or empty pcDNA3 plasmids linearized by 
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ScaI restriction endonuclease (Boehringer Mannheim, Mannheim, Germany). Genetycin-resistant clones 
were selected after ~20 days by adding 0.4 mg/ml G418 (Invitrogen) to the culture medium. HaCaT 
clones expressing SOCS1-2 or -3 proteins were selected by Western blot analysis with the anti-c-myc 
Ab. 
 
4.8 Cristal violet assay  
Primary keratinocyte cells (2x104) were seeded in 96-well plates, and, the day after, starved in KBM. 
Culture stimulation with IL-22 was conducted either in the presence or absence of 10 µM Ex-527 or 40 
µM Resveratrol (both from Sigma-Aldrich). SIRT1-silenced cells were also used in some experiments. 
Moreover, SOCS1-3 stable clones were seeded in 96-well plates (1.5x104 cells/well), and, the day after, 
starved in DMEM without serum. Culture stimulation with 70 ng/ml of IL-22 was conducted. After 2–4 
d of treatment, cells were stained with 0.5% crystal violet, whose incorporation was measured at 540 nm 
in an ELISA reader (model 3550 UV ELISA reader; Bio-Rad, Hercules, CA, USA). 
 
4.9 Scratch wound healing assays 
Keratinocytes were STAT3 or SIRT1 grown at 100% of confluence, and then scratched with the tip of a 
p-200 pipette to create a uniform cell-free zone. Wounded monolayers were either incubated or not with 
30 ng/ml IL-22. Microscopy pictures were taken with a digital camera at different time points following 
IL-22 treatment. The residual gap between migrating keratinocytes was measured with a computer-
assisted image analysis system (Axiovision, Zeiss, Oberkochen, Germany), and expressed as percentage 
of the initial scratched area. 
 
4.10 Immunohistochemistry 
Cryostatic sections were incubated with monoclonal antibodies (mAbs) against SIRT1 (E104; Abcam, 
Cambridge, UK) and CD3 (BD-Pharmingen, Franklin Lakes, NJ, USA). Secondary biotinylated mAbs 
and staining kits (Vector Laboratories, Burlingame, CA, USA) were used to develop immunoreactivity. 
Figures depict one experiment that is representative of all the patients investigated. 
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5. Results (1) 
5.1 IL-22 induces chemokines, antimicrobial peptides and proliferative molecules but inhibits 
differentiative markers in human keratinocytes. 
IL-22 controls several biological processes in keratinocytes, including proliferation differentiation, 
migration, and production of molecules involved in the innate immune responses [26]. In particular, IL-
22 was able to up-regulate mRNA expression of the chemokines CXCL8 and CXCL1 as well as the 
antimicrobial peptide HBD-2 and the S100A7, with significant levels of induction at late time points of 
stimulation (24–48 h; Fig. 5.1A). IL-22 also induced high amounts of SOCS3, which was rapidly 
induced (1 h), but did not affect SOCS1 mRNA expression. In parallel, it has been found that IL-22 
could not regulate the membrane expression of ICAM-1, MHC class I and II molecules, induced by 36h 
of treatment with IFN-γ and TNF-α (Fig. 5.1B). Although IL-22 is considered a potent inducer of 
epidermal hyperplasia in pathological conditions, little information exists about its effect on the 
induction of molecules controlling keratinocyte proliferation. To this end, IL-22-treated keratinocytes 
were analyzed for the expression of proteins inducing cell cycle progression and, thus, essential for cell 
proliferation [59]. As shown in Fig. 5.1C, IL-22 maintained high nuclear levels of PCNA, cyclin D1 and 
pRB after 9 and 24 h, as compared to untreated cultures, which showed a decreased expression at these 
time points. In parallel, IL-22 could block the down-regulation of KRT5 and KRT14, two cytokeratins 
typical of proliferating keratinocytes, in cultures undergoing terminal differentiation (4 d of growth after 
confluence; Fig. 5.1D). Vice versa, IL-22 inhibited the expression of KRT1, a structural protein highly 
present in keratinocytes committed to terminal differentiation (Fig. 5.1D). IL-22 also potently decreased 
the protein accumulation of loricrin, which is a component of the cross-linked cell envelope in the 
uppermost layers of the epidermis (Fig. 5.1D).  
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Figure 5.1A: IL-22-induces many inflammatory genes in human cultured keratinocytes. CXCL8, 
CXCL1, HBD-2, S100A7, SOCS3, and SOCS1 mRNA expression was evaluated by Real-time PCR 
analysis of mRNA from samples untreated or stimulated with IL-22 (50 ng/ml), and normalized to β-
actin mRNA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1B: IL-22 does not control the expression of immune-modulatory molecules in 
keratinocytes. Cytofluorymetric analysis of ICAM1, MHC Class I and Class II in 36 h stimulated 
culture keratinocytes with IL-22 (50 ng/ml), IFN-γ (200 U/ml) or TNF-α (50 ng/ml). 
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Figure 5.1C: IL-22 induces the nuclear translocation of PCNA, cyclin D1 and pRB proteins in 
human keratinocytes. PCNA, cyclin D1, and pRB levels were evaluated by Western blotting in 
cytosols or nuclei prepared from keratinocytes either treated or not with IL-22. Proper fractionation  
of nuclei and cytosols was verified by analyzing lamin A/C and tubulin expression, respectively. 
Graphs represent densitometric analyses of nuclear PCNA, cyclin D1, and pRB. Data are expressed 
as mean ± SD fold induction (F.I.), calculated relative to the untreated samples (t0), which were 
given a value of 1. *P < 0.05. 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 5.1D: IL-22 opposes the reduction of markers of keratinocyte proliferation whereas 
reduces markers of keratinocyte differentiation. Keratinocyte cultures were grown at 100% of 
confluence (t0) and left in culture for another 4 d in presence or absence of IL-22. Total lysates were 
analyzed by Western blotting using anti-KRT1, anti-KRT5, anti-KRT14, or anti-loricrin Abs. 
Graphs represent densitometric analyses of total KRT1, KRT5, KRT14, and loricrin normalized to 
β-actin signals. *P <0.05; **P < 0.01. 
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5.2 STAT3 is the main mediator of IL-22-induced effects in human keratinocytes. 
The analysis of IL-22-induced molecular cascades demonstrated that STAT3 signaling was rapidly 
induced in primary cultures of keratinocytes, and, in particular, STAT3 phosphorylation in Tyr705 was 
observed after 15–30 min of treatment with IL-22 (Fig. 5.2A). STAT3 phosphorylation in Ser727 
residue, constitutively detected in keratinocytes, was also enhanced by IL-22, showing peculiar biphasic 
kinetics (Fig. 5.2A). IL-22 did not affect STAT1 activation but significantly induced extracellular 
signal-regulated kinase (ERK) 1/2 phosphorylation after 30 min of treatment (Fig. 5.2A). To determine 
whether STAT3 expression and activation influenced the IL-22-induced regulation of CXCL8, CXCL1, 
HBD-2, S100A7, SOCS3, and of the proteins associated to keratinocyte proliferation and differentiation, 
STAT3 mRNA silencing was performed in IL-22-activated or untreated keratinocyte cultures (Fig. 
5.2B). Following silencing of STAT3 mRNA, keratinocytes were not able to up-regulate SOCS3 mRNA 
in response to IL-22 treatment, but continued to express HBD-2 and S100A7 (Fig. 5.2C). In parallel, 
CXCL8 and CXCL1 were only slightly induced by IL-22, indicating that STAT3 positively regulates 
these genes, but other mechanisms can control their expression. In addition, considering the delayed 
kinetics of CXCL8 and CXCL1 induction by IL-22, it is plausible that the STAT3 effect on these genes 
was indirect. Also, the nuclear accumulation of PCNA, cyclin D1, and pRB proteins observed after 24 h 
of incubation with IL-22 was significantly dependent on STAT3 expression (Fig. 5.2D). The negative 
effect of IL-22 on KRT1 expression did not occur when cells were STAT3 depleted (Fig. 5.2E). 
Similarly to KRT1, loricrin expression substantially increased in keratinocytes silenced for STAT3 (Fig. 
5.2E), suggesting that STAT3 acts as a repressor of these molecules. On the contrary, the modulation of 
KRT5 and KRT14 expression by IL-22 treatment was independent from STAT3 (Fig. 5.2E). STAT3 
mRNA and protein silencing by siRNA in keratinocytes was substantial and specific since STAT1 
expression was unchanged (Fig. 5.2B). In summary, these data indicated that the majority of the IL-22-
induced effects in human keratinocytes were mediated by STAT3 signaling. 
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Figure 5.2A: In keratinocytes IL-22 induces STAT3 and ERK1/2 activation. Total STAT3, 
STAT3 phosphorylated in Tyr705 and in Ser727, total STAT1, STAT1 phosphorylated in Tyr701, 
total ERK1/2, and ERK1/2 phosphorylated in Tyr204 were detected by Western blotting. Immunoblot 
stainings are representative of 3 independent experiments performed on 3 different keratinocyte 
strains. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2B: STAT3 transient silencing in cultured keratinocytes.  Keratinocyte cultures were 
transfected with siRNA specific for STAT3 or irrelevant siRNA (NC). After 48 h transfection, cells 
were stimulated with IL-22 or not for the indicated time periods. Analyses of STAT3 and STAT1 
protein accumulation or mRNA expression were performed by Western blotting or real-time PCR, 
respectively. 
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Figure 5.2C: SOCS3, and at less extent, CXCL1 and CXCL8, are induced by IL-22 treatment in a 
STAT3-dependent manner. CXCL8, CXCL1, HBD-2, S100A7, and SOCS3 mRNA expression was 
analyzed in samples silenced for STAT3 or treated with NC siRNA and then stimulated with IL-22 as 
indicated. *P < 0.05; **P < 0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2D: The IL-22-triggered nuclear translocation of proliferative markers is a STAT3-
dependent event in keratinocytes. Western blotting of nuclei and cytosols served to study PCNA, cyclin 
D1, and pRB protein accumulation in untreated or IL-22-stimulated keratinocytes transfected with 
irrelevant and STAT3-specific siRNA. Graphs represent densitometric analyses of nuclear PCNA, cyclin 
D1, and pRB. Western blots are representative of 3 independent experiments performed on 3 different 
keratinocyte strains. *P < 0.05. 
 
 
 
30 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2E: The IL-22-derived reduction of differentiative markers in keratinocytes is STAT3-
dependent. STAT3-silenced keratinocyte cultures undergoing terminal differentiation (4 d) either 
activated or not with IL-22 were studied for KRT1, KRT5, KRT14, and loricrin expression by Western 
blotting. Graphs show densitometric values of KRT1, KRT5, KRT14, and loricrin. Western blots are 
representative of 3 independent experiments performed on 3 different keratinocyte strains. *P < 0.05; 
**P < 0.01. 
 
 
 
 
5.3 SIRT1 inhibits STAT3 activation by reducing its Lys685 acetylation. 
STAT3 is tightly regulated at the post-translational level, and, in particular, its acetylation in Lys685 is 
indispensable for the phosphorylation in Tyr705 and trans-activating function [30]. Lys685 acetylation 
of STAT3 can be, in turn, inhibited by SIRT1, which is also known to reduce proliferation and promote 
terminal differentiation of epidermal keratinocytes [39, 42]. Therefore, we supposed that SIRT1 and/or 
other sirtuin members could oppose IL-22 signaling and effects on keratinocytes by inhibiting STAT3 
acetylation in Lys685 and, thus, STAT3 phosphorylation and function. We firstly analyzed the 
expression of the seven sirtuin members in cultured healthy keratinocytes. Semi-quantitative PCR 
analysis demonstrated that keratinocytes constitutively expressed substantial levels of SIRT1, SIRT2, 
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SIRT5 and SIRT7 mRNA, and very low or null levels of SIRT3, SIRT4 and SIRT6 mRNA (Fig. 5.3.A). 
The manipulation of SIRT1-2-5 and -7 by transient RNA interference demonstrated that only SIRT1 
could significantly up-regulate STAT3 activation. In fact, SIRT1- but not SIRT2- or SIRT5- or SIRT7-
depleted keratinocytes showed higher levels of phosphorylated STAT3 (Tyr 705) in response to IL-22 
compared to control cells (Fig. 5.3B). Conversely, SIRT1 depletion did not affect the phosphorylation in 
Ser727 of STAT3 nor the activation of STAT1 and ERK1/2 (Fig. 5.3C). In addition, the analysis of 
STAT3 activity in IL-22-treated SIRT1-silenced keratinocytes transfected with a STAT3-responsive 
plasmid, pLucTKS3, revealed that SIRT1 negatively regulates STAT3 activity (Fig. 5.3D, Left graph). 
On the contrary, SIRT1 overexpression by transfection with a human SIRT1-encoding plasmid dose-
dependently inhibited the pTKS3 luciferase activity (Fig. 5.3D, Right graph). Since SIRT1 opposed IL-
22 effects by counteracting STAT3 phosphorylation in Tyr705, the capability of SIRT1 to modulate 
STAT3 acetylation was also studied. Firstly, STAT3 acetylation in Lys685 was analyzed by Western 
blotting in keratinocytes untreated or activated with IL-22. STAT3 acetylation was constitutive and not 
modulated by IL-22 (Fig. 5.3E). When keratinocytes were depleted of SIRT1, Lys685 constitutive 
acetylation of STAT3 was significantly enhanced compared to control cells, as assessed using different 
keratinocyte strains (n=3) and in independent experiments of silencing (3 representative experiments are 
shown in Fig. 5.3F). The effect of SIRT1 was specific since SIRT7 did not influence STAT3 acetylation 
in Lys685 (Fig. 5.3F). Collectively, these data demonstrated that SIRT1 negatively modulates STAT3 
capability to control the expression of molecules regulated by IL-22 by inhibiting Lys685 acetylation of 
STAT3 and, thus, its phosphorylation in Tyr705. 
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Figure 5.3A: Primary cultures of human keratinocytes highly express SIRT1-2-5 and -7 mRNA, 
and low or null levels of SIRT3-4 and -6. SIRT1-SIRT7 mRNA expression was evaluated in 
untreated cultured keratinocytes by semi-quantitative PCR analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3B: Among sirtuins only SIRT1 reduces the IL-22-derived Tyr705 phosphorylation of 
STAT3. Keratinocyte cultures were transfected with SIRT1-, SIRT2-, SIRT5-, SIRT7-specific or 
irrelevant siRNA. After 48-h transfection, cells were stimulated with IL-22 or not, as indicated. 
Analyses of STAT3 phosphorylated in Tyr705 (pY-STAT3) and total STAT3 were performed by 
Western blotting. 
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Figure 5.3C: SIRT1 does not influence the IL-22-induced STAT3 Ser727 and ERK1/2 Tyr204 
phosphorylation. Keratinocyte cultures were transfected with SIRT1-specific or irrelevant siRNA. 
After 48 h transfection, cells were stimulated with IL-22 or not, as indicated. Analyses of STAT3 
phosphorylated in Tyr705 (pY-STAT3) and in Ser727 (pS-STAT3), total STAT3, total ERK1/2, and 
ERK1/2 phosphorylated in Tyr204 were performed by Western blotting. Densitometries of blots relative 
to pY-STAT3, pS-STAT3, and phosphorylated ERK1/2 are shown. 
 
 
 
 
 
 
 
 
 
 
Figure 5.3D: IL-22-induced STAT3 activity is counterregulated by SIRT1. Left graph. 
Keratinocytes were treated with irrelevant siRNA or with siRNA specific for SIRT1, at 3 or 30 nM 
concentrations. Cells were then transiently transfected with pTKS3-Luc reporter plasmid and 
stimulated with IL-22. Effects of SIRT1 depletion on the STAT3-responsive plasmid were evaluated by 
assaying luciferase activity. Right graph. Cultured keratinocytes were cotransfected with increasing 
amounts (0–2 µg/well) of pcDNA3.1 (open bars) or pcDNA3-hSIRT1-FLAG (solid bars), and of 0.5 
µg pTKS3-Luc reporter plasmid; 3 independent experiments. Data are expressed as means ± SD of 
Firefly luciferase values normalized to Renilla luciferase and micrograms of total proteins. *P<0.05; 
**P <0.01. 
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Figure 5.3E: In keratinocytes STAT3 is constitutively acetylated in Lys685 residue. STAT3 
acetylation in Lys685 [AcK(685)-STAT3] was analyzed by Western blotting performed on untreated or 
IL-22-activated keratinocytes. Blots are representative of 3 independent experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3F: SIRT1 deacetylates STAT3 in Lys685 in keratinocytes. STAT3 acetylation in Lys685 
was analyzed by Western blotting by using lysates from keratinocytes transfected with siRNAs specific 
for SIRT1 or SIRT7, and compared to NC. Results are representative of 6 independent experiments. 
Densitometry of blot relative to AcK(685)-STAT3 is shown. *P <0.05; **P <0.01 
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5.4 IL-22-induced STAT3-dependent gene expression as well as proliferative and migratory 
processes in keratinocytes are counteracted by SIRT1. 
To further clarify the role of SIRT1 in the control of IL-22-induced STAT3-dependent gene expression 
in keratinocytes, we manipulated SIRT1 mRNA expression through RNA interference. We found that 
SIRT1 silencing in IL-22-treated keratinocytes strongly up-regulated SOCS3 mRNA expression (Fig. 
5.4A). CXCL8 and CXCL1 expression also increased in SIRT1-depleted keratinocytes compared to 
control cells (Fig. 5.4A). As expected, HBD-2 and S100A7 gene expression, which were not STAT3-
dependent, were not influenced by SIRT1 silencing (Fig. 5.4A). Consistently, SIRT1-depletion 
enhanced the positive effect of IL-22 on PCNA, cyclin D1 and pRB nuclear translocation, which 
occurred in a STAT3-dependent manner (Fig. 5.4B). SIRT1-silencing also determined a marked 
reduction of KRT1 and loricrin expression in keratinocytes undergoing differentiation, in agreement 
with previous findings [42] (Fig. 5.4C). Of note, SIRT1 depletion reinforced the inhibitory effect of IL-
22 on KRT1 expression (Fig. 5.4C). Finally, KRT5 and KRT14 up-regulation by IL-22 in keratinocytes 
undergoing differentiation in vitro, an event found to be independent from STAT3 (Fig. 5.2E), was not 
affected by SIRT1 silencing (Fig. 5.4C). To clarify the role of SIRT1 in the control of IL-22-induced 
keratinocyte proliferation, a functional in vitro assay measuring the keratinocyte proliferative rate was 
performed after the manipulation of SIRT1 function and expression by using chemical modulators of 
SIRT1 or through RNA interference, respectively. Crystal violet tests on keratinocyte cultures treated 
with Ex-527, a specific inhibitor of SIRT1 enzymatic activity, or with resveratrol, a polyphenol 
stimulating SIRT1 deacetylase function, showed that SIRT1 significantly opposed IL-22-induced 
keratinocyte proliferation (Fig. 5.4D, Left graph). Consistently, SIRT1-silenced keratinocytes 
proliferated more actively in response to IL-22 compared to cells transfected with irrelevant siRNA 
(Fig. 5.4D, Right graph). It has previously reported that IL-22 promotes wound healing in an in vitro 
injury model [11]. Therefore, SIRT1 ability to counteract IL-22 also in this system was studied, and it 
has been found that SIRT1 silencing in keratinocytes greatly enhanced IL-22-induced wound healing 2d 
after scratching (Fig. 5.4E). Since the IL-22-induced closure of keratinocyte layer was strictly STAT3-
dependent, as assessed by mRNA interference of STAT3 (Fig. 5.4E), it is likely that the negative effects 
of SIRT1 on IL-22-induced wound healing occurred through STAT3 inhibition. 
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Figure 5.4A: SIRT1 counteracts the IL-22-derived and STAT3-dependent expression of SOCS3, 
CXCL1 and CXL8. Keratinocyte cultures were transfected with SIRT1-specific or irrelevant siRNA, 
and then stimulated with IL-22 or not, as indicated. CXCL8, CXCL1, HBD-2, S100A7, and SOCS3 
mRNA expression was analyzed by real-time PCR. *P <0.05; **P <0.01. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4B: SIRT1 inhibits the IL-22-derived and STAT3-dependent nuclear translocation of 
proliferative markers. Keratinocyte cultures were transfected with SIRT1-specific or irrelevant 
siRNA, and, then, 24-h stimulated with IL-22 or not. PCNA, cyclin D1, and pRB were analyzed by 
Western blotting. Graphs show densitometric values of PCNA, cyclin D1 and pRB staining on blots. 
Western blots are representative of 3 independent experiments performed on 3 different keratinocyte 
strains. *P < 0.05. 
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Figure 5.4C: SIRT1 counteracts the IL-22-induced and STAT3-dependent inhibition of 
differentiative marker expression. Keratinocyte cultures were transfected with SIRT1-specific or 
irrelevant siRNA, and, then, 4-d stimulated with IL-22 or not. KRT1, Loricrin, KRT5 and KRT14 were 
analyzed by Western blotting.  *P < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4D: Positive effect of IL-22 on keratinocyte proliferation is counteracted by SIRT1.  
Proliferation of keratinocytes treated with 10 µM Ex-527 or 40 µM resveratrol either in presence or 
absence of IL-22 was proportional to crystal violet incorporation (Left graph). Crystal violet assay was 
also performed on keratinocytes transfected with SIRT1 or irrelevant siRNA and treated with IL-22 
(Right graph). Crystal violet incorporation was measured with an ELISA reader after 2 d of culture and is 
expressed as fold induction of treated vs. untreated samples, which were given a value of 1. *P < 0.05; 
**P < 0.01. 
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Figure 5.4E: Positive effect of IL-22 on keratinocyte migration is counteracted by SIRT1.  Scratch 
assays were carried out on keratinocytes silenced for STAT3 (STAT3si) or SIRT1 (SIRT1si) or treated 
with irrelevant siRNA (NCsi), and incubated or not with 30 ng/ml IL-22 for 48 h. Residual gap 
between migrating keratinocytes is expressed as percentage of initial scratched area. *P <0.01 vs. NCsi 
samples; **P < 0.01 vs. IL-22-treated NCsi samples. 
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5.5 SIRT1 expression in keratinocytes is down-regulated in psoriatic skin and, in vitro, after IFN-γ 
exposure. 
STAT3 activity is enhanced in skin affected by psoriasis, especially in response to IL-22, and is 
responsible for the hyperproliferation and altered differentiation of the psoriatic epidermis [5]. Since 
SIRT1 efficiently controls IL-22-induced activity of STAT3 in keratinocytes, it has been investigated if 
SIRT1-STAT3 interplay in psoriasis could be deregulated. Therefore, SIRT1 expression levels were first 
analyzed in keratinocyte strains obtained from patients with psoriasis, and compared them with 
keratinocytes isolated from skin of healthy individuals. Keratinocyte cultures were prepared from LS 
and NLS skin biopsies obtained from the same donor. As shown in Figure 5.5A, patients with psoriasis 
and healthy donors showed similar SIRT1 levels, mainly localized in the cytosol, as assessed by 
Western blotting. Immunohistochemistry analysis confirmed that SIRT1 was cytosolic and uniformly 
expressed in keratinocytes of the basal layer of the epidermis (Fig. 5.5Bi–iii). The pattern of SIRT1 
expression was identical in healthy and NLS psoriatic skin (Fig. 5.5Bi, ii), which showed also few 
infiltrating CD3+ T cells (Fig. 5.5Biv, v). Conversely, basal keratinocytes of LS psoriasis exhibited a 
reduced and less intense SIRT1 staining if compared to healthy and NLS skin, especially at the tips of 
the epidermal papillae close to the CD3+ T cell infiltrate (Fig. 5.5Biii, vi). Since T cells infiltrating 
psoriatic lesions produce very high amounts of IFN-γ (i.e., Th1, Th1/Th17 and T cytotoxic cells), it has 
been hypothesized that SIRT1 decrement in LS psoriatic keratinocytes could be due to local T-cell-
derived IFN-γ. Indeed, treatment of keratinocyte cultures with supernatants obtained from Th1 clones 
releasing high amounts of IFN-γ (25–35 ng/ml/106 cells) reduced SIRT1 protein expression (Fig. 5.5C). 
Keratinocyte treatments with recombinant cytokines typically present in psoriatic skin confirmed that 
only recombinant IFN-γ, and not TNF-α, IL-17, or IL-22, could reduce SIRT1 mRNA and protein 
expression in human keratinocytes (Fig. 5.5C). As a whole, these data demonstrate that although SIRT1 
is expressed at comparable levels in keratinocytes from patients with psoriasis and healthy individuals, it 
is down-regulated in psoriatic epidermis, likely as a result of the local overexpression of IFN-γ. 
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Figure 5.5A: SIRT1 in vitro expression is cytosolic and it is comparable in healthy and psoriatic 
keratinocytes.  Cultured keratinocytes were prepared from healthy skin or from biopsies taken from 
uninvolved (NLS KC) or involved (LS KC) psoriatic skin. SIRT1 protein level was detected in total 
(Left panels) or fractionated (Right panels) lysates of keratinocytes; 3 of 6 representative psoriatic and 
healthy keratinocyte strains are shown. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.5B: SIRT1 in vivo expression is reduced in psoriatic epidermal papillae close to the Th1 
lymphocytes. Immunohistochemistry for SIRT1 and CD3 (both stained in red) was performed on 
frozen sections from biopsies of psoriatic skin including LS (ii, v), and NLS (iii, vi) areas of plaques. 
Healthy skin was also analyzed (i, iv). Immunoreactivity was revealed by using 3-amino-9-
ethylcarbazole as substrate. Arrows (iii) indicate area of epidermal papillae where SIRT1 staining was 
reduced. Representative stainings of 6 psoriatic sections analyzed are shown. 
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Figure 5.5C: IFN-γ reduces the SIRT1 expression levels. Western blotting of SIRT1 performed on 
keratinocyte cultures after 24 h activation with diluted (1:3) supernatants derived from 3 Th1 clones 
(AC1.36, FN2.26, and RS3.7) that produce high amounts of IFN-γ (25–35 ng/ml/106 cells). Th1 clones 
were prepared from peripheral blood of patients with psoriasis; and supernatants were collected after 48 
h activation with anti-CD3 and anti-CD28. Alternatively, SIRT1 expression was analyzed by real-time 
PCR or Western blotting in samples activated with recombinant IFN-γ, TNF-α, IL-17 or IL-22 (right 
panels). Western blots are representative of 2 independent experiments performed on 2 different 
keratinocyte strains. *P < 0.01. 
 
 
 
5.6 IFN-γ up-regulates basal STAT3 acetylation, thus reinforcing the IL-22-induced STAT3 
phosphorylation and downstream effects in keratinocytes. 
To see whether the reduced SIRT1 expression by IFN-γ could result in an increase of STAT3 
acetylation and, thus, in enhanced STAT3 phosphorylation in response to IL-22, Western blotting 
experiments were performed on keratinocyte cultures prestimulated with IFN-γ or TNF-α, and then 
activated with IL-22. As shown in Fig. 5.6A, IFN-γ significantly enhanced basal STAT3 acetylation in 
Lys685 (lane 2 vs. 1) as well as the IL-22-induced phosphorylation of STAT3 in Tyr705, as compared to 
treatment with IL-22 alone (lane 5 vs. 4). The effect was specific for IFN-γ since TNF-α could not 
regulate neither basal STAT3 acetylation (Fig. 5.6 A, lane 3 vs. 1) nor IL-22-induced STAT3 
phosphorylation (Fig. 5.6A, lane 6 vs. 4). Accordingly, SIRT1 silencing in keratinocytes further 
enhanced the IFN-γ-induced acetylation in Lys685 of STAT3 (Fig. 5.6A). Concomitantly to the up-
regulation of IL-22-induced STAT3 phosphorylation, IFN-γ strengthened IL-22-promoted downstream 
effects. In particular, IFN-γ significantly enhanced IL-22-induced expression of CXCL8, CXCL1, and 
SOCS3 mRNA (Fig. 5.6B), as well as IL-22-inhibited accumulation of KRT1 (Fig. 5.6C). Interestingly, 
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nuclear PCNA was strongly reduced by IFN-γ (Fig. 5.6D), which notoriously exerts an antiproliferative 
effect on keratinocytes [60]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.6A: IFN-γ up-regulates basal STAT3 Lys685 acetylation. Cultured keratinocytes were 
pretreated for 24 h with IFN-γ or TNF-α, then stimulated with IL-22 for 30 min. Total lysates were 
analyzed by Western blotting; amounts of acetyl STAT3 and phosphorylated STAT3 were analyzed by 
densitometry. Analyses of acetyl STAT3 were also performed on keratinocytes transfected with 
irrelevant or SIRT1 siRNA and activated for 24 h with IFN-γ or TNF-α. *P < 0.01. 
 
 
 
 
 
 
 
 
Figure 5.6B: IFN-γ reinforces the IL-22-triggered inflammatory gene expression. CXCL8, CXCL1, 
and SOCS3 mRNA expression was evaluated by real-time PCR in cultured keratinocytes 24h pre-
treated with IFN-γ and then stimulated with IL-22 for indicated time. *P < 0.05; **P < 0.01. 
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Figure 5.6C: IFN-γ potentiates the IL-22-derived KRT1 reduction. KRT1 expression analysis was 
performed on keratinocyte cultures undergoing terminal differentiation or stimulated with IL-22 and/or 
IFN-γ for 4 d. Variations of KRT1 levels were also determined by densitometry. Western blots are 
representative of 2 independent experiments performed on 2 different keratinocyte strains. *P <0.05. 
 
 
 
 
 
 
 
 
 
Figure 5.6D: IFN-γ has anti-proliferative effects in keratinocytes. Nuclear PCNA was analyzed in 
keratinocytes treated with IL-22 and/or IFN-γ for 24 h. Western blots are representative of 2 
independent experiments performed on 2 different keratinocyte strains. *P <0.05. 
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6. Results (2) 
6.1 SOCS3 is induced by IL-22 and inhibits the cytokine-dependent STAT3 activation in 
keratinocytes. 
It has previously reported that IL-22 is able to induce SOCS3 in hepatic cells [55], but nothing is known 
about the modulation of SOCS3 expression by the cytokine in human epidermal keratinocytes. For this 
purpose, mRNA expression of SOCS family members was firstly analyzed in IL-22-activated 
keratinocytes. We found that IL-22 rapidly induced high amounts of SOCS3 mRNA (Fig. 6.1A), 
whereas the expression of the other SOCS could not be affected by cytokine treatment. Next, we 
manipulated the SOCS3 expression by transient RNA interference in cultured keratinocytes and 
analyzed the IL-22-triggered STAT3 activation. SOCS3-silenced cells showed a significant increase of 
STAT3 Tyr705 phosphorylation after IL-22 treatment compared to cells transfected with irrelevant 
siRNA (Fig. 6.1B, left panels). Conversely, SOCS3 depletion did not affect the phosphorylation in 
Ser727 of STAT3. To better clarify the involvement SOCS molecules in the control of IL-22-induced 
STAT3 activation, the keratinocyte-like cell line HaCaT was stably transfected with plasmids encoding 
c-myc-tagged SOCS1, SOCS2, or SOCS3 molecules. Genetycin-resistant clones were screened for 
SOCS expression levels, and four SOCS1 clones, two SOCS2 clones and three SOCS3 clones were 
obtained and included in the study. SOCS3 keratinocyte clones strongly reduced the IL-22-mediated 
STAT3 phosphorylation in Tyr705 but not in Ser727 residue (Fig. 6.1B, right panels). Interestingly, 
even though SOCS1 was not up-regulated by IL-22, STAT3 Tyr705 phosphorylation was greatly 
inhibited in all keratinocyte clones expressing SOCS1, whereas no differences were observed for cells 
permanently transfected with SOCS2 (Fig. 6.1B, right panels). Keratinocyte clones expressed 
comparable levels of SOCS1, SOCS2, and SOCS3 proteins (Fig. 6.1B, right panels). In addition, 
transient transfections of keratinocytes with SOCS1 or SOCS3 plasmids markedly reduced the IL-22-
induced transactivation of the STAT3-responsive plasmid pTKS3-Luc (Fig. 6.1C). In contrast, transient 
SOCS2 overexpression in keratinocytes had no effects on STAT3 activity.  
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Figure 6.1A: SOCS3 is rapidly induced by IL-22 in keratinocytes. Real-time PCR analyses for 
CIS and SOCS1-7 were performed on reverse-transcribed RNA from primary culture of keratinocytes 
treated with IL-22 as indicated. *P <0.05. 
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Figure 6.1B: SOCS3 inhibits the IL-22-induced STAT3 Tyr705 phosphorylation. Western blotting 
performed on lysates from SOCS3-silenced primary keratinocytes (left panels) or HaCaT cells stably 
transfected with SOCS1, SOCS2 or SOCS3 plasmids (right panels) activated or not with IL-22 for the 
indicated time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1C: IL-22-dependent STAT3 activity is counter-regulated by SOCS3. Representation of 
luciferase activity of keratinocytes transiently co-transfected with the pTKS3Luc and SOCS1, SOCS2, 
SOCS3 or empty (MOCK) plasmids. Cultures were treated or not with IL-22 for 8-h. 3 independent 
experiments were performed. Data are expressed as means ± SD of Firefly luciferase values normalized 
to Renilla luciferase and micrograms of total proteins. *P<0.05. 
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6.2 SOCS3 inhibits the IL-22-induced inflammatory gene expression and proliferative effects in 
keratinocytes. 
Since an inhibitory effect of SOCS3 on IL-22-dependent STAT3 activation was observed, the possible 
role of the molecule in regulating the expression of STAT3-dependent genes induced by IL-22 in 
keratinocytes was evaluated. As expected, SOCS3 mRNA silencing in IL-22-treated keratinocytes up-
regulated the expression of CXCL1 and CXCL8 mRNA compared to control cells (Fig. 6.2A). In 
addition, HBD-2 gene expression, which was not STAT3-dependent, was also positively influenced by 
SOCS3 silencing (Fig. 6.2A). To clarify the role of SOCS3 in the control of IL-22-induced keratinocyte 
proliferation, Crystal violet tests were performed on cultured keratinocytes after the manipulation of 
SOCS3 expression. SOCS3-silenced keratinocytes proliferated more actively in resting condition as well 
as in response to IL-22 compared to cells transfected with irrelevant siRNA (Fig. 6.2B, left graph). Vice 
versa, SOCS3 overexpressing keratinocytes were quite totally resistant to the strong proliferative effect 
induced by IL-22 3-d of stimulation (Fig. 6.2B, right graph). Consistently with STAT3 inhibition data, 
SOCS1 clones did not respond to the proliferative effects of IL-22. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2A: The expression of IL-22-induced genes is reduced by SOCS3. SOCS3, CXCL8, 
CXCL1 and HBD-2 mRNA expression was analyzed in samples silenced for SOCS3 or treated with NC 
siRNA and then stimulated with IL-22 as indicated. *P<0.05. 
 
48 
 
 
 
 
 
 
 
 
 
 
Figure 6.2B: SOCS3 inhibits the IL-22-mediated keratinocyte proliferation. Crystal violet assay 
was performed on keratinocytes transfected with SOCS3 or irrelevant siRNA and 3-d treated with IL-22 
(left graph). Proliferation was also analyzed in SOCS3, SOCS1 or MOCK stably transfected cells kept 
in culture for 3 d in the presence or absence of IL-22. Proliferation was then analyzed by measuring at a 
spectrophotometer the incorporation of the crystal violet dye. Data are expressed as fold-induction of 
IL-22-treated over untreated samples, which were given a value of 1. *P < 0.05. 
 
 
 
 
6.3 SOCS3 inhibitory effect on IL-22-induced STAT3 activation is mediated by SOCS3-KIR 
domain. 
The last step was to identify SOCS3 regions responsible for the abrogation of the IL-22-triggered 
STAT3 activity executed by SOCS3. For this purpose, the pTKS3 luciferase activity was measured in 
cultured keratinocytes transiently transfected with plasmids encoding SOCS3 mutated in different 
domains, and then stimulated with IL-22 for 8 h. In particular, dN25 (KIR-deleted), dN36 (KIR- and 
part of ESS-deleted), L22D (single-mutation in KIR), R71E (single-mutation in SH2) and dC40 (SOCS 
box-deleted) plasmids were used in this study. We observed that a single amino acid mutation in 
SOCS3-KIR domain was sufficient to abrogate the inhibitory effect of the wild-type SOCS3 (WT) on 
the IL-22-induced pTKS3 luciferase activity (Fig. 6.3). In parallel, a significantly up-regulation in 
STAT3 transcriptional activity was found by trasfecting keratinocytes with dN25 and dN36 KIR-
deleted plasmids. In addition, the expression of the SOCS3-SH2 mutant (R71E) in keratinocytes, which 
abrogated the SOCS3 capability to bind protein targets, also enhanced the luciferase activity of the 
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STAT3 responsive plasmid compared to cells expressing SOCS3 WT. Conversely, dC40 plasmid, in 
which SOCS-Box region was deleted, more efficiently inhibited the IL-22-mediated STAT3 luciferase 
activity compared to the SOCS3 WT. This was due to the fact that the SOCS-Box deletion impeded the 
proteasome-degradation of SOCS3, therefore enhancing its levels. All these data suggested that the 
SOCS3-KIR domain has a pivotal role in the SOCS3 inhibitory effect on IL-22 signaling in 
keratinocytes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.3: SOCS3 KIR domain is pivotal in the inhibition of the IL-22-dependent STAT3 
transcriptional activity. Representation of luciferase activity of keratinocytes transiently co-transfected 
with the pTKS3Luc and SOCS3 WT, dN25, dN36, L22D, R71E, dC40 or empty plasmids. Cultures 
were treated or not with IL-22 for 8 hours. 3 independent experiments were performed. Data are 
expressed as means ± SD of Firefly luciferase values normalized to Renilla luciferase and micrograms 
of total proteins*P < 0.05; **P < 0.01. 
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7. Discussion 
Psoriasis results from complex, aberrant relationships between the skin and immune system as well as 
genetic predisposition and environmental factors [2]. Epidermal keratinocytes of psoriatic skin show an 
exaggerated wound healing response and an aberrancy of STAT3 activation in keratinocytes has been 
proposed for the pathogenesis of psoriasis [61]. Indeed, STAT3 is activated in keratinocytes of psoriatic 
patients [31]. This up-regulation of STAT3 activation in psoriasis does not appear to be a secondary 
outcome of epidermal hyperplasia, because lesions from non-psoriatic inflammatory skin diseases with 
characteristic acanthosis show a STAT3 staining pattern similar to normal epidermis. In addition, 
increased levels of cytokines or growth factors that promote STAT3 activation have been found within 
psoriatic lesions [5, 61]. Among them, IL-22 potently triggers STAT3 activation and consequently alters 
the proliferative and differentiative processes in keratinocytes, and induces inflammatory molecules 
[24]. Therefore, the inhibition of IL-22-induced STAT3 activation in keratinocytes could be a valid 
strategy for the treatment of psoriasis. Besides phosphorylation on tyrosine 705 and serine 727 sites 
within the carboxyl-terminal region, STAT3 proper activation requires the acetylation on a single lysine 
residue 685, which is executed by histone acetyl transferase p300 [19, 20]. The acetylation of STAT3 
was found to be critical for it to form stable dimers, which are required for cytokine-stimulated DNA 
binding and transcriptional regulation. STAT3 activation is negatively regulated through numerous 
mechanisms. These involve deacetylase enzymes, SOCS molecules, protein inhibitor of activated STAT 
(PIAS), protein phosphatases, and ubiquitination-dependent proteosomal degradation [62]. In this study 
we analyzed the role of SIRT1 deacetylase enzyme and SOCS3 molecule in the control of the IL-22-
induced and STAT3-dependent effects in human keratinocytes. It is well known that SIRT1 can regulate 
the acetylation status and, thus, the phosphorylation and function of several transcription factors, 
including p53, E2F1, NF-κB, c-Jun, and members of the FoxO family [63]. Interestingly, Nie et al. [39] 
have described the involvement of SIRT1 in promoting STAT3 Lys685 deacetylation, and, thus, in 
down-regulating STAT3 phosphorylation and activity in hepatocytes during gluconeogenesis. STAT3 
acetylation is rarely found in resting cells but it can be efficiently induced by cytokines, such as 
oncostatin M, IL-6, and by type I IFNs [35]. Conversely, we found that in keratinocytes STAT3 is 
constitutively acetylated in Lys685 residue, which is indispensable for the IL-22-triggered STAT3 
activation. SIRT1 negatively regulated STAT3 acetylation, and consequently inhibited the IL-22-
induced STAT3 phosphorylation in Tyr705. 
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In line with previous works suggesting that SOCS3 is a negative-feedback regulator of cytokine-induced 
STAT3 activation [51], we found that, other than SIRT1, also SOCS3 inhibited the IL-22-induced 
STAT3 Tyr705 phosphorylation in keratinocytes. SIRT1, PIAS proteins and protein tyrosine 
phosphatases target STAT3 directly, whereas SOCS3 through its KIR domain down-regulated the 
upstream kinase activity responsible for STAT3 phosphorylation. Therefore, it is reasonable to think 
that SOCS3 potentially could block some IL-22-activated signaling pathways other than STAT3. 
Moreover, both SIRT1 and SOCS3 inhibited IL-22-induced STAT3 transcriptional activity and as a 
direct consequence, reduced the STAT3-dependent expression of CXCL1 and CXCL8 chemokines. We 
also found that SIRT1 decreased the IL-22-induced and STAT3-dependent nuclear translocation of 
typical markers of keratinocyte proliferation (PCNA, cyclin D1, and pRB) as well as it increased the 
levels of markers of keratinocyte differentiation (KRT1 and loricrin). Since IL-22 exerts a mitogenic 
activity in keratinocyte cells [17], we then evaluated if SIRT1 and SOCS3 could also regulate the 
cytokine-induced biological effects in cultured keratinocytes. Through the manipulation of SIRT1 and 
SOCS3 expression, we found that these molecules opposed the IL-22-mediated proliferation of cultured 
keratinocytes. In addition, SIRT1 counteracted the cytokine-derived wound healing. Since the IL-22-
induced closure of keratinocyte layer was strictly dependent on STAT3, it is possible that the negative 
effects of SIRT1 on IL-22-induced wound healing were explicated through the inhibition of STAT3 
acetylation. SIRT1 inhibitory function on proliferative processes of keratinocytes is consistent with 
previous data demonstrating that the enzyme is an inhibitor of keratinocyte proliferation and an inducer 
of keratinocyte differentiation [42]. The anti-proliferative role of SOCS3 was in line with a previous 
work demonstrating that keratinocytes from transgenic mice over-expressing SOCS3 show a reduced 
migration and proliferation in vitro [64]. From the in vivo analysis of SIRT1 expression we found that it 
was mainly localized at the basal layer of the epidermis of both healthy and psoriatic skin, where 
keratinocytes have a high mitotic activity. In fact, SIRT1 drives proliferative keratinocytes to the 
differentiative programs necessary for the formation of the upper layers of the epidermis. However, 
compared to healthy and not lesional psoriatic skin, the expression of SIRT1 was reduced in the basal 
layer of lesional epidermis especially at the tips of the epidermal papillae close to the IFN-γ- producing 
CD3+ T-cell infiltrate. IFN-γ reduced SIRT1 expression also in vitro and as a consequence it enhanced 
STAT3 Lys685 acetylation. Moreover, IFN-γ pretreatment of keratinocyte cultures strongly enhanced 
STAT3 phosphorylation in Tyr705 and STAT3-dependent gene expression induced by IL-22. The 
amplificatory effect of IFN-γ on IL-22 signaling in keratinocytes is analogous to that promoted by TNF-
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α, even if the molecular mechanisms and genes regulated by the combination of IL-22 and TNF-α are 
completely different [11]. The specificity of IFN-γ and TNF-α effects on IL-22 signaling could depend 
on their ability to regulate and activate different molecular pathways. Concerning STAT3, TNF-α, 
differently from IFN-γ, did not affect its phosphorylation nor acetylation. Other than potentiating IL-22 
signaling in keratinocytes, IFN-γ was also able to counteract IL-22-induced downstream effects in 
keratinocytes. In fact, it could reduce both basal and IL-22-promoted PCNA nuclear accumulation, 
accordingly to its potent anti-proliferative effect on this cell type. Therefore, IFN-γ can either potentiate 
or inhibit IL-22 signaling, with this dual effect depending on the IFN-γ ability to induce, in addition to 
STAT3 acetylation, other molecular cascades. Among these, STAT1 activation, usually associated with 
a decrease in proliferation rate in IFN-γ-sensitive cells, could be responsible for the dominant inhibitory 
effect of IFN-γ on IL-22-induced PCNA expression. It would be important to evaluate whether IFN-γ 
has a prevailing role also on IL-22-induced proliferation in keratinocytes, and whether psoriatic 
keratinocytes are less or more sensitive than healthy cells to the anti-proliferative or mitogenic effect of 
IFN-γ and IL-22, respectively. Indeed, previous studies have already shown that psoriatic keratinocytes 
aberrantly respond to IFN-γ, whose injection into uninvolved psoriatic skin causes epidermal 
hyperplasia and plaque development [65]. The enhanced proliferative response of psoriatic keratinocytes 
to IFN-γ has been supposed to rely on a reduced activation of STAT1 signaling and on an altered 
expression level of the IFN-γ receptor complex in the epidermis of psoriatic lesions compared to healthy 
skin [66]. 
Although, SOCS3 was highly expressed in the epidermis of psoriatic skin (data not shown), this was not 
sufficient to inhibit the detrimental effects triggered by IL-22 and other pathogenetic cytokines in 
keratinocytes. Importantly, we have demonstrated that SOCS3 not only exerts protective effects through 
the inhibition of STAT3 activation, but it was also able to sustain the IL-22-triggered activation of 
ERK1/2, which drives pro-survival programs in keratinocytes and could ultimately contribute to the 
expression of the peculiar epidermal thickening of psoriatic skin. The enhancement of the IL-22-induced 
ERK1/2 phosphorylation could be executed by SOCS3 similarly to the mechanism described by 
Madonna et al. for SOCS1 in IFN-γ-derived ERK1/2 activation [56]. We think that SOCS3, through its 
SOCS-Box domain, induced the degradation of Ras-Gap, the activation of Ras and finally the 
phosphorylation of ERK1/2. 
Taken together these data suggest that the use of activators of SIRT1 or molecules able to specifically 
mimic the SOCS3-KIR region, capable to decrease STAT3 activation in epidermal keratinocytes, may 
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be therapeutically relevant for the treatment of psoriasis but also for other skin diseases characterized by 
aberrant STAT3 activation. The latter include cutaneous tumors, such as papilloma and squamous cell 
carcinoma, where STAT3 has a role in the tumor promotion stage of epithelial carcinogenesis [67]. 
Indeed, STAT3 inhibition by STAT3 decoy oligonucleotides in mice harboring activated STAT3 
abrogated the de novo generation of tape stripping-induced psoriatic lesions in mice overexpressing 
STAT3 in the epidermis as well as the development of TPA-induced skin carcinoma [5, 61, 67]. In 
addition, the STAT3 inhibitor STA-21 molecule, an antibiotic which blocks STAT3 dimerization and 
DNA binding, has been successfully employed in a pilot study for the treatment of psoriasis [32].  
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STAT3-dependent effects of IL-22 in human
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ABSTRACT IL-22 has a pathogenetic role in psoria-
sis, where it is responsible for the altered proliferation
and differentiation of keratinocytes and induces in-
flammatory molecules. The IL-22-induced effects are
mediated by STAT3, whose activity is proportional to
acetylation in lysine (Lys)685 and phosphorylation in
tyrosine (Tyr)705. Lys 685 acetylation of STAT3 is
inhibited by sirtuin (SIRT)1, a class III deacetylase
promoting keratinocyte differentiation. Due to the op-
posite effects of IL-22 and SIRT1, we investigated
whether IL-22-induced effects in keratinocytes could be
regulated by SIRT1 through control of STAT3. We
found that SIRT1 opposes the IL-22-induced STAT3
activity by deacetylating STAT3 and reducing STAT3
Tyr705 phosphorylation. By controlling STAT3, SIRT1
also influences the IL-22-induced expression of mole-
cules involved in proliferation and inflammation as well
as proliferation and migration processes in cultured
keratinocytes. Although SIRT1 levels were similar in
keratinocytes of healthy individuals and patients with
psoriasis, they were reduced in psoriatic skin lesions,
with the lymphokine IFN- inhibiting SIRT1 expres-
sion. Concomitantly, IFN- enhanced basal acetylation
of STAT3 and its phosphorylation induced by IL-22. In
conclusion, STAT3-dependent IL-22 signaling and ef-
fects in keratinocytes are negatively regulated by
SIRT1. In skin affected by psoriasis, SIRT1 is down-
regulated by IFN-, which thus renders psoriatic kera-
tinocytes more prone to respond to IL-22.—Sestito, R.,
Madonna, S., Scarponi, C., Cianfarani, F., Failla, C. M.,
Cavani, A., Girolomoni, G., Albanesi, C. STAT3-depen-
dent effects of IL-22 in human keratinocytes are
counterregulated by sirtuin 1 through a direct inhibi-
tion of STAT3 acetylation. FASEB J. 25, 000 – 000
(2011). www.fasebj.org
Key Words: class III histone deacetylase (HDAC)  post-trans-
lational modification  psoriasis  skin inflammation  IFN-
IL-22 is a member of the IL-10 family preferentially
produced by a subset of T-helper (Th)1 and Th17 cells
(1, 2), and by the recently identified Th22 subset (3–5).
IL-22 acts through a heterodimeric receptor containing
the IL-10 receptor (R)2 and IL-22R1 chains (6). IL-
10R2 is widely expressed on immune cells, whereas
IL-22R1 expression is restricted to nonhematopoietic
cells, such as epidermal keratinocytes and epithelial
cells of the gastrointestinal tract and the lung (7, 8).
IL-22 has been considered as a key cytokine in psoriasis,
an immune-mediated skin disease characterized by a
marked epidermal hyperplasia associated with altered
keratinocyte differentiation (9–11). In psoriasis, IL-22
mediates keratinocyte proliferation, inhibits keratino-
cyte terminal differentiation, and stimulates the pro-
duction of antimicrobial peptides and chemokines (9–
11). STAT3 is the principal mediator of IL-22 signaling
(9); its levels are increased in psoriatic epidermis, and
overexpression of STAT3 in keratinocytes determines a
psoriatic phenotype in transgenic mice (12). STAT3
activation requires STAT3 phosphorylation in Tyr705
and in Ser727 residues (13), and can be counterregu-
lated by the suppressor of cytokine signaling (SOCS)3
in a classic feedback loop (14). Notably, STAT3 activa-
tion is proportional to acetylation in Lys685 residue,
since this post-translational modification is required for
phosphorylation in Tyr705 (15). Acetylation of STAT3
relies on a tight balance between acetylation and
deacetylation performed primarily by p300 acetylase
and histone deacetylase (HDAC) enzymes, respectively
(15). In particular, SIRT1, the best characterized mem-
ber of class III HDACs, mediates deacetylation of the
STAT3 Lys685 site and, in turn, negatively regulates
STAT3 phosphorylation in Tyr705 (16). Recently, it has
been shown that SIRT1 is an important inducer of
keratinocyte differentiation and inhibitor of keratino-
cyte proliferation (17). These SIRT1-mediated effects
are specific of keratinocytes and are not shared by other
cell types, such as white adipocytes and myocytes, where
1 Correspondence: Laboratory of Experimental Immunol-
ogy, Istituto Dermopatico dell’Immacolata (IDI)-IRCCS, Via
Monti di Creta, 104, 00167 Rome, Italy. E-mail: c.albanesi@
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SIRT1 overexpression counteracts differentiative pro-
cesses (18, 19).
Due to the opposite effects of IL-22 and SIRT1 in
keratinocytes, we investigated whether IL-22-induced
molecular signaling, gene expression, and proliferation
could be regulated by SIRT1 through direct control of
STAT3 acetylation and phosphorylation. Specifically,
we analyzed the effects of SIRT1 on IL-22-regulated
expression of genes involved in proliferation, innate
immunity, and inflammation, and genes typical of
initial and terminal epidermal differentiation, with a
particular interest in STAT3-dependent genes. We
found that SIRT1 opposed STAT3 activation and
STAT3-dependent effects of IL-22 on keratinocytes, by
deacetylating STAT3 and reducing STAT3 phosphory-
lation in Tyr705. Although SIRT1 levels were similar in
cultured keratinocytes isolated from skin of healthy
individuals and patients with psoriasis, they were re-
duced in vivo in the epidermal papillae of psoriatic
lesions, especially in areas closer to the inflammatory
CD3 T-cell infiltrate. It is worth noting that IFN-,
mostly released by Th1 cells infiltrating psoriatic skin,
inhibited SIRT1 expression and, concomitantly, en-
hanced STAT3 Lys685 acetylation and phosphorylation
in Tyr705, rendering keratinocytes more prone to
express IL-22-inducible genes.
MATERIALS AND METHODS
Tissue samples
For immunohistochemistry, 4-mm punch biopsies were taken
from lesional (LS) skin of adult patients with chronic plaque
psoriasis (n6) and from normal skin of healthy subjects
undergoing plastic surgery (n4). For patients with psoriasis,
a skin biopsy from nonlesional (NLS) skin distant from the
plaques was also taken. Keratinocyte cultures were established
from 6-mm biopsies obtained from both involved and unin-
volved skin of patients with psoriasis (n6) and from healthy
control subjects (n8). T-cell clones were established from
the peripheral blood of 3 patients with psoriasis. The study
was approved by the Ethical Committee of the IDI-IRCCS
(Rome, Italy).
Immunohistochemistry
Cryostatic sections were incubated with monoclonal antibod-
ies (mAbs) against SIRT1 (E104; 1:100 dilution; Abcam,
Cambridge, UK) or CD3 (1:20 dilution; BD-Pharmingen,
Franklin Lakes, NJ, USA). Secondary biotinylated mAbs and
staining kits (Vector Laboratories, Burlingame, CA, USA)
were used to develop immunoreactivity. Figures depict one
experiment that is representative of all the patients investi-
gated.
Keratinocyte cultures and treatments
Primary cultures of human keratinocytes were obtained from
skin biopsies, as described previously (20). Keratinocyte cul-
tures were grown in serum-free keratinocyte growth medium
(KGM; Clonetics, Walkersville, MD, USA), for 3–5 d (at
60–80% confluence) before performing experiments. Stim-
ulations with 50 ng/ml IL-22, 200 U/ml IFN-, 50 ng/ml
TNF-, or 50 ng/ml IL-17 (all from R&D Systems, Minneap-
olis, MN, USA) were performed in keratinocyte basal medium
(KBM, Clonetics). Subconfluent cultures were also stimulated
with supernatants from Th1 clones or RPMI medium diluted
1:3 in KBM. Terminal differentiation of keratinocyte cultures
was achieved by growing cells at 100% of confluence (t0) and,
thus, keeping them in culture for another 4 d. Keratinocytes
undergoing differentiation were also cultured in the presence
of IL-22 and/or IFN-.
Preparation of supernatants from T-cell clones obtained
from patients with psoriasis
CD4 T-cell clones were obtained from peripheral blood of
patients with psoriasis, as described previously (21). Cells
were periodically stimulated with 1% phytohemagglutinin
(Invitrogen, Carlsbad, CA, USA), and were activated with
plate-coated anti-CD3 and soluble anti-CD28 (both at 1
g/ml). Clone supernatants were assayed for IFN-, TNF-,
IL-17, IL-22, and IL-4 content with a commercially available
ELISA kit (R&D Systems). Clones were classified depending
on their cytokine profile, and supernatants of Th1 clones
containing levels of IFN-  20 ng/ml were used on keratino-
cyte cultures.
RNA isolation and real-time polymerase chain
reaction (PCR)
Total RNA was extracted using the TRIzol reagent (Invitrogen),
and analyzed by real-time PCR. The expression of CXCL8,
CXCL1, SOCS3, SOCS1, S100A7, HBD-2, STAT3, STAT1,
SIRT1, and -actin mRNA were evaluated in the ABI Prism SDS
7000 PCR instrument (Applied Biosystems, Branchburg, NJ,
USA), using SYBR Green PCR reagents or Taqman PCR Master
Mix. The forward and reverse primers employed for real-time
PCR were as follows: for CXCL8, 5-GCTGGCTTATCTTCAC-
CATCATG-3 and 5-TTATTTTTTTTCAGTTAATTAACAGAT-
GCTATCAT-3; for SOCS3, 5-AAGGACGGAGACTTCGAT-
TCG-3 and 5-AAACTTGCTGTGGGTGACCAT-3; for SOCS1,
5-TTTTTCGCCCTTAGCGTGA-3 and 5-AGCAGCTCGAA-
GAGGCAGTC-3; for STAT3, 5-GGCGTCACTTTCACTT-
GGGT-3 and 5-CCACGGACTGGATCTGGGT-3; for STAT1,
5-TTGCTTGGATCAGCTGCAGA-3 and 5-GCTGCA-
GACTCTCCGCAACTA-3; for SIRT1, 5-GCTGGCCTAATA-
GAGTGGCAA-3 and 5-CTCAGCGCCATGGAAAATG-3, for
-actin, 5-CATCGAGCACGGCATCGTCA-3 and 5-
TAGCACAGCCTGGATAGCAAC-3. The sequences of the
primers and internal probe for HBD-2 mRNA have been previ-
ously described (22). Primers for CXCL1 and S100A7 were
provided by Applied Biosystems (Hs00236937 and Hs00161488,
respectively). The levels of gene expression were determined by
normalizing to -actin mRNA expression. The values obtained
from triplicate experiments were averaged, and data are pre-
sented as means 	 sd.
Flow cytometry analysis
Keratinocyte expression of membrane intercellular adhesion
molecule (ICAM)-1, major histocompatibility complex (MHC)
class I and II was evaluated using FITC-conjugated anti-CD54
(84H10; Immunotech, Marseille, France), anti-HLA-ABC (G46-
2.6; BD-Pharmingen) and anti-HLA-DR (L243; BD-Pharmin-
gen) mAbs. Cells were analyzed with a FACScan equipped with
Cell Quest software (Becton Dickinson, Mountain View, CA,
USA).
2 Vol. 25 March 2011 SESTITO ET AL.The FASEB Journal  www.fasebj.org
Western blot analysis
Total proteins and cytosolic and nuclear extracts were pre-
pared as previously reported (20), and subjected to SDS-
PAGE. Western blotting filters were developed using the
ECL-plus detection system (Amersham, Du¨bendorf, Switzer-
land) or the SuperSignal West Femto kit (Pierce, Rockford,
IL, USA). The Abs employed for the study were as follows:
anti-PCNA (PC10), anti-cyclin D1 (DCS-6), anti-phospho-RB
(Ser795), anti-lamin A/C (346), anti--tubulin (B-7), anti--
actin (C-11), anti-phospho-STAT3 (Ser727), anti-STAT3 (C-
20), anti-phospho-STAT1 (Tyr701), anti-STAT1 (E-23), anti-
phospho-ERK1/2 (E-4), anti-ERK1/2 (C16), and anti-SIRT1
(H-300), all provided by Santa Cruz Biotechnology (Santa
Cruz, CA, USA). Anti-KRT1, anti-KRT5, anti-KRT14, and
anti-loricrin Abs were from Covance (Emeryville, CA, USA),
whereas anti-phospho-STAT3 (Tyr705) and anti-acetyl-STAT3
(K685) were from Cell Signaling Technology (Danvers, MA,
USA). Finally, anti-FLAG (M2) and anti-SIRT7 (RB1973)
were purchased from Sigma-Aldrich (Saint Louis, MO, USA)
and Abgent (San Diego, CA, USA), respectively.
Transient RNA interference, transfections, and luciferase
assay
STAT3, SIRT1, and SIRT7 were knocked down by using a pool
of 4 small short interfering (si)RNAs (ON-TARGETplus SMART-
pool, Dharmacon RNA Technology, Lafayette, CO, USA). In
parallel, a pool of 4 nontargeting siRNAs was used as negative
control. Primary cultures were transfected with STAT3, SIRT1,
SIRT7, or irrelevant siRNA using Interferin reagent (Polyplus
Transfection, New York, NY, USA). After 2 d of mRNA silencing,
keratinocytes were treated with different stimuli. Cultured kera-
tinocytes grown in 12-well plates were transiently transfected
with the STAT3-responsive plasmid pLucTKS3 (a generous gift
of Prof. J. Turkson, University of Central Florida, Orlando, FL,
USA) by using Lipofectin reagent (Invitrogen). After transfec-
tion, cells were stimulated with IL-22, and Firefly luciferase
activity was measured using the Dual-Glo Luciferase Assay Sys-
tem (Promega, Madison, WI, USA). pRL-null plasmid encoding
the Renilla luciferase was included in each transfection. For
dose-response experiments with pcDNA3-hSIRT1-FLAG (kindly
provided by Prof. F. Ishikawa, Kyoto University, Kyoto, Japan),
cells were transfected with pLucTKS3 plasmid and pRL-null
vector, using the pcDNA3.1 plasmid as negative control. STAT3-
driven luciferase activity of pLucTKS3 plasmid was also assayed
in cultured keratinocytes transfected with SIRT1 siRNA.
Crystal violet assay
Cells (2
104) were seeded in 96-well plates, and, the day after,
starved in KBM. Culture stimulation with IL-22 was conducted
either in the presence or absence of 10 M Ex-527 or 40 M
resveratrol (both from Sigma-Aldrich). SIRT1-silenced cells were
also used in some experiments. After 2–4 d of treatment, cells
were stained with 0.5% crystal violet, whose incorporation was
measured at 540 nm in an ELISA reader (model 3550 UV ELISA
reader; Bio-Rad, Hercules, CA, USA).
Scratch wound healing assay
Keratinocytes were STAT3 or SIRT1 silenced, grown at 100% of
confluence, and then scratched with the tip of a p-200 pipette to
Figure 1. IL-22-regulated genes and molecular
signaling in human keratinocytes. A) CXCL8,
CXCL1, HBD-2, S100A7, SOCS3, and SOCS1 mRNA
expression were evaluated by real-time PCR analysis
of samples untreated or stimulated with IL-22 (50
ng/ml), and normalized to -actin mRNA. B) PCNA,
cyclin D1, and pRB levels were evaluated by Western
blotting in cytosols or nuclei prepared from keratin-
ocytes either treated or not with IL-22. Proper frac-
tionation of nuclei and cytosols was verified by analyzing lamin A/C and tubulin expression, respectively. Graphs represent
densitometric analyses of nuclear PCNA, cyclin D1, and pRB. Data are expressed as mean 	 sd fold induction (F.I.), calculated
relative to the untreated samples (t0), which were given a value of 1. C) Keratinocyte cultures were grown at 100% of confluence
(t0) and left in culture for another 4 d in presence or absence of IL-22. Total lysates were analyzed by Western blotting using
anti-KRT1, anti-KRT5, anti-KRT14, or anti-loricrin Abs. Graphs represent densitometric analyses of total KRT1, KRT5, KRT14,
and loricrin normalized to -actin signals. D) Total STAT3, STAT3 phosphorylated in Tyr705 and in Ser727, total STAT1, STAT1
phosphorylated in Tyr701, total ERK1/2, and ERK1/2 phosphorylated in Tyr204 were detected by Western blotting.
Immunoblot stainings are representative of 3 independent experiments performed on 3 different keratinocyte strains.
*P  0.05; **P  0.01.
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create a uniform cell-free zone. Wounded monolayers were
either incubated or not with 30 ng/ml IL-22. Microscopy pic-
tures were taken with a digital camera at different time points
following IL-22 treatment. The residual gap between migrating
keratinocytes was measured with a computer-assisted image
analysis system (Axiovision; Zeiss, Oberkochen, Germany), and
expressed as percentage of the initial scratched area.
Densitometry and statistical analysis
Phospho-STAT3, acetyl-STAT3, PCNA, cyclin D1, pRB, KRT1,
KRT5, KRT14, loricrin, and phospho-ERK1/2 immunoblots
were subjected to densitometry using an imaging densitometer
(GS-670; Bio-Rad). The significance of differences between
densitometric values was determined by Wilcoxon’s signed rank
test (SigmaStat; Jandel, San Rafael, CA, USA). This test was also
used to calculate the significance of differences between kera-
tinocytes transfected with irrelevant and SIRT1-specific siRNAs
as well as between cultures transfected with SIRT1-encoding and
control plasmids in luciferase assays. Comparison of CXCL8,
CXCL1, S100A7, HBD-2, and SOCS3 expression between kera-
tinocytes transfected with irrelevant and SIRT1- or STAT3-
specific siRNA, and of SIRT1 mRNA levels between untreated
and cytokine-stimulated cultured cells was performed. Signifi-
cant differences were also calculated for scratched cultures of
keratinocytes. Values of P  0.05 were considered significant.
RESULTS
Main mediator of IL-22-induced effects in human
keratinocytes is STAT3
IL-22 controls several biological processes in keratino-
cytes, including proliferation, differentiation, migra-
tion, and production of molecules involved in the
innate immune responses (23, 24). Our study of gene
Figure 2. Majority of IL-22-regulated molecules in keratinocytes are STAT3-dependent. A) Keratinocyte cultures were
transfected with siRNA specific for STAT3 or irrelevant siRNA (NC). After 48 h transfection, cells were stimulated with IL-22 or
not for the indicated time periods. Analyses of STAT3 and STAT1 protein accumulation or mRNA expression were performed
by Western blotting or real-time PCR, respectively. B) CXCL8, CXCL1, HBD-2, S100A7, and SOCS3 mRNA expression were
analyzed in samples silenced for STAT3 or treated with NC siRNA. C) Western blotting of nuclei and cytosols served to study
PCNA, cyclin D1, and pRB protein accumulation in untreated or IL-22-stimulated keratinocytes transfected with irrelevant and
STAT3-specific siRNA. Graphs represent densitometric analyses of nuclear PCNA, cyclin D1, and pRB. D) STAT3-silenced
keratinocyte cultures undergoing terminal differentiation (4 d) either activated or not with IL-22 were studied for KRT1, KRT5,
KRT14, and loricrin expression by Western blotting. Graphs show densitometric values of KRT1, KRT5, KRT14, and loricrin.
Western blots are representative of 3 independent experiments performed on 3 different keratinocyte strains. *P  0.05; **P  0.01.
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and protein expression regulated by IL-22 in cultured
human keratinocytes extended previous analyses (23,
24) and showed that IL-22 was able to up-regulate
mRNA expression of CXCL8, CXCL1, HBD-2, and
S100A7, with significant levels of induction at late time
points of stimulation (24–48 h; Fig. 1A). IL-22 also
induced high amounts of SOCS3, which was rapidly
induced (1 h), but did not affect SOCS1 mRNA expres-
sion. In parallel, we found that IL-22 could not regulate
the membrane expression of ICAM-1, MHC class I and
II molecules, induced by IFN- and TNF- (data not
shown). Although IL-22 is considered a potent inducer
of epidermal hyperplasia in pathological conditions,
little information exists about its effect on the induc-
tion of molecules controlling keratinocyte prolifera-
tion. To this end, IL-22-treated keratinocytes were
analyzed for the expression of proteins inducing cell
cycle progression and, thus, essential for cell prolifera-
tion (25). As shown in Fig. 1B, IL-22 maintained high
nuclear levels of PCNA, cyclin D1 and pRB after 9 and
24 h, as compared to untreated cultures, which showed
a decreased expression at these time points. In parallel,
IL-22 could block the down-regulation of KRT5 and
KRT14, two cytokeratins typical of proliferating keratino-
cytes, in cultures undergoing terminal differentiation
(4 d of growth after confluence; Fig. 1C). Vice versa,
IL-22 inhibited the expression of KRT1, a structural
protein highly present in keratinocytes committed to
terminal differentiation (Fig. 1C). IL-22 also potently
decreased the protein accumulation of loricrin, which
is a component of the cross-linked cell envelope in the
uppermost layers of the epidermis (Fig. 1C). The
analysis of IL-22-induced molecular cascades demon-
strated that STAT3 signaling was rapidly induced in
primary cultures of keratinocytes, and, in particular,
STAT3 phosphorylation in Tyr705 was observed after
15–30 min of treatment with IL-22 (Fig. 1D). STAT3
phosphorylation in Ser727 residue, constitutively de-
tected in keratinocytes, was also enhanced by IL-22,
showing a peculiar biphasic kinetics (Fig. 1D). IL-22 did
not affect STAT1 activation but significantly induced
extracellular signal-regulated kinase (ERK)1/2 phos-
phorylation after 30 min of treatment (Fig. 1D).
To determine whether STAT3 expression and activa-
tion influenced the IL-22-induced regulation of CXCL8,
CXCL1, HBD-2, S100A7, SOCS3, and of the proteins
associated to keratinocyte proliferation and differentia-
tion, STAT3 mRNA silencing was performed in IL-22-
activated or untreated keratinocyte cultures (Fig. 2A).
Following silencing of STAT3 mRNA, keratinocytes were
not able to up-regulate SOCS3 mRNA in response to
IL-22 treatment, but continued to express HBD-2 and
S100A7 (Fig. 2B). In parallel, CXCL8 and CXCL1 were
only slightly induced by IL-22, indicating that STAT3
positively regulates these genes, but other mechanisms
can control their expression. In addition, considering the
delayed kinetics of CXCL8 and CXCL1 induction by
IL-22, it is plausible that the STAT3 effect on these genes
was indirect. Also, the nuclear accumulation of PCNA,
cyclin D1, and pRB proteins observed after 24 h of
incubation with IL-22 was significantly dependent on
STAT3 expression (Fig. 2C). The negative effect of IL-22
on KRT1 expression did not occur when cells were STAT3
depleted (Fig. 2D). Similarly to KRT1, loricrin expression
substantially increased in keratinocytes silenced for
STAT3 (Fig. 2D), suggesting that STAT3 acts as a repres-
sor of these molecules. On the contrary, the modulation
of KRT5 and KRT14 expression by IL-22 treatment was
independent from STAT3 (Fig. 2D). STAT3 mRNA and
protein silencing by siRNA in keratinocytes was substantial
Figure 3. IL-22-induced STAT3 phosphorylation
in Tyr705 and activity is counterregulated by
SIRT1. A) Keratinocyte cultures were transfected
with SIRT1-specific or irrelevant siRNA. After
48 h transfection, cells were stimulated with IL-22
or not, as indicated. Analyses of STAT3 phosphor-
ylated in Tyr705 (pY-STAT3) and in Ser727 (pS-
STAT3), total STAT3, total ERK1/2, and ERK1/2
phosphorylated in Tyr204 were performed by
Western blotting. Densitometries of blots relative
to pY-STAT3, pS-STAT3, and phosphorylated
ERK1/2 are shown. B) Keratinocytes were treated
with irrelevant siRNA or with siRNA specific for
SIRT1, at 3 or 30 nM concentrations. Cells were
then transiently transfected with pTKS3-Luc re-
porter plasmid and stimulated with IL-22. Effects
of SIRT1 depletion on the STAT3-responsive
plasmid were evaluated by assaying luciferase ac-
tivity. C) Cultured keratinocytes were cotrans-
fected with increasing amounts (0–2 g/well) of
pcDNA3.1 (open bars) or pcDNA3-hSIRT1-FLAG
(solid bars), and of 0.5 g pTKS3-Luc reporter
plasmid; 3 independent experiments. Data are
expressed as means 	 sd of Firefly luciferase
values normalized to Renilla luciferase and micro-
grams of total proteins. *P  0.05; **P  0.01.
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and specific since STAT1 expression was unchanged (Fig.
2A). In summary, these data indicated that the majority of
the IL-22-induced effects in human keratinocytes were
mediated by STAT3 signaling.
SIRT1 opposes STAT3 activation and
STAT3-dependent gene expression regulated by
IL-22 in keratinocytes through the inhibition of
STAT3 acetylation in Lys685
STAT3 is tightly regulated at the post-translational
level, and, in particular, its acetylation in Lys685 is
indispensable for the phosphorylation in Tyr705 and
trans-activating function (15). Lys 685 acetylation of
STAT3 can be, in turn, inhibited by SIRT1, which is also
known to reduce proliferation and promote terminal
differentiation of epidermal keratinocytes (16, 17).
Therefore, we hypothesized that SIRT1 could oppose
IL-22 signaling and effects on keratinocytes by inhibit-
ing STAT3 acetylation in Lys685 and, thus, STAT3
phosphorylation and function. To this end, we manip-
ulated SIRT1 expression by RNA silencing and ana-
lyzed STAT3 phosphorylation and activation after IL-22
treatment. SIRT1-silenced cells showed a significant
up-regulation of STAT3 phosphorylation in Tyr705
residue compared to cells transfected with irrelevant
siRNA (Fig. 3A). In contrast, SIRT1 depletion did not
affect the phosphorylation in Ser727 of STAT3 nor the
activation of STAT1 and ERK1/2 (Fig. 3A). In addition,
the analysis of STAT3 activity in IL-22-treated SIRT1-
silenced keratinocytes transfected with a STAT3-re-
sponsive plasmid, pLucTKS3, revealed that SIRT1 neg-
atively regulates STAT3 activity (Fig. 3B). On the
contrary, SIRT1 overexpression by transfection with a
human SIRT1-endoding plasmid dose-dependently in-
hibited the pTKS3 luciferase activity (Fig. 3C). These
Figure 4. SIRT1 counteracts IL-22-regulated STAT3-dependent gene expression in keratinocytes. Keratinocyte cultures were
transfected with SIRT1-specific or irrelevant siRNA, and then stimulated with IL-22 or not, as indicated. A) CXCL8, CXCL1,
HBD-2, S100A7, and SOCS3 were analyzed by real-time PCR. B) PCNA, cyclin D1, and pRB were analyzed by Western blotting.
C) KRT1, KRT5, KRT14, and loricrin proteins were also analyzed in keratinocytes committed to terminal differentiation. Graphs
show densitometric values of PCNA, cyclin D1, pRB, KRT1, KRT5, KRT14, and loricrin staining on blots. Western blots are
representative of 3 independent experiments performed on 3 different keratinocyte strains. *P  0.05; **P  0.01.
6 Vol. 25 March 2011 SESTITO ET AL.The FASEB Journal  www.fasebj.org
results led us to investigate the possible role of SIRT1 in
regulating the expression of STAT3-dependent genes
induced by IL-22 in keratinocytes. SIRT1 silencing in
IL-22-treated keratinocytes strongly up-regulated SOCS3
mRNA expression (Fig. 4A). CXCL8 and CXCL1 expres-
sion also increased in SIRT1-depleted keratinocytes com-
pared to control cells (Fig. 4A). As expected, HBD-2 and
S100A7 gene expression, which were not STAT3-depen-
dent, were not influenced by SIRT1 silencing (Fig. 4A).
Consistently, SIRT1-depletion enhanced the positive ef-
fect of IL-22 on PCNA, cyclin D1 and pRB nuclear
translocation, which occurred in a STAT3-dependent
manner (Fig. 4B). SIRT1-silencing also determined a
marked reduction of KRT1 and loricrin expression in
keratinocytes undergoing differentiation, in agreement
with previous findings (17) (Fig. 4C). Of note, SIRT1
depletion reinforced the inhibitory effect of IL-22 on
KRT1 expression (Fig. 4C). Finally, KRT5 and KRT14
up-regulation by IL-22 in keratinocytes undergoing
differentiation in vitro, an event found to be indepen-
dent from STAT3 (Fig. 2D), was not affected by
SIRT1 silencing (Fig. 4C).
The finding that SIRT1 opposes IL-22 effects by
counteracting STAT3 phosphorylation in Tyr705 led us
to investigate the capability of SIRT1 to modulate
STAT3 acetylation. We first analyzed STAT3 acetylation
in Lys685 by Western blotting in keratinocytes un-
treated or activated with IL-22. STAT3 acetylation was
constitutive and not modulated by IL-22 (Fig. 5A).
When keratinocytes were depleted of SIRT1, Lys685
constitutive acetylation of STAT3 was significantly en-
hanced compared to control cells, as assessed using
different keratinocyte strains (n3) and in indepen-
dent experiments of silencing (3 representative exper-
iments are shown in Fig. 5B). The effect of SIRT1 was
specific since SIRT7, another sirtuin family member,
did not influence STAT3 acetylation in Lys685 (Fig.
5B). Collectively, these data demonstrated that SIRT1
negatively modulates STAT3 capability to control the
expression of molecules regulated by IL-22 by inhibit-
ing Lys685 acetylation of STAT3 and, thus, its phos-
phorylation in Tyr705.
IL-22-induced keratinocyte proliferation and
migration is counteracted by SIRT1
To further clarify the role of SIRT1 in the control of
IL-22-induced keratinocyte proliferation, we manipulated
SIRT1 function and expression by using chemical modu-
lators of SIRT1 or through RNA interference, respectively,
and performed functional in vitro assays measuring the
keratinocyte proliferative rate. Crystal violet tests on ker-
atinocyte cultures treated with Ex-527, a specific inhibitor
of SIRT1 enzymatic activity, or with resveratrol, a polyphe-
nol stimulating SIRT1 deacetylase function, showed that
SIRT1 significantly opposed IL-22-induced keratinocyte
proliferation (Fig. 6A). Consistently, SIRT1-silenced kera-
tinocytes proliferated more actively in response to IL-22
compared to cells transfected with irrelevant siRNA (Fig.
6A, bottom graph). Our previous findings showed that
IL-22 promoted wound healing in an in vitro injury model
(5). Therefore, we tested SIRT1 ability to counteract IL-22
also in this system, and found that SIRT1 silencing in
keratinocytes greatly enhanced IL-22-induced wound
healing 2 d after scratching (Fig. 6B). Since the IL-22-
induced closure of keratinocyte layer was strictly STAT3-
dependent, as assessed by mRNA interference of STAT3
(Fig. 6B), it is likely that the negative effects of SIRT1 on
IL-22-induced wound healing occurred through STAT3
inhibition.
SIRT1 expression in keratinocytes is down-regulated
in psoriatic skin and, in vitro, on IFN- exposure
STAT3 activity is enhanced in skin affected by psoriasis,
especially in response to IL-22, and is responsible for the
hyperproliferation and altered differentiation of the pso-
riatic epidermis (12). Since SIRT1 efficiently controls
IL-22-induced activity of STAT3 in keratinocytes, we asked
whether SIRT1-STAT3 interplay in psoriasis could be
deregulated. Therefore, we first analyzed SIRT1 expres-
sion levels in keratinocyte strains obtained from patients
with psoriasis, and compared them with keratinocytes
isolated from skin of healthy individuals. Keratinocyte
cultures were prepared from LS and NLS skin biopsies
obtained from the same donor. As shown in Fig. 7A,
patients with psoriasis and healthy donors showed similar
SIRT1 levels, mainly localized in the cytosol, as assessed by
Western blotting. Immunohistochemistry analysis con-
firmed that SIRT1 was cytosolic and uniformly expressed
in keratinocytes of the basal layer of the epidermis (Fig.
7Bi–iii). The pattern of SIRT1 expression was identical in
healthy and NLS psoriatic skin (Fig. 7Bi, ii), which showed
also few infiltrating CD3 T cells (Fig. 7Biv, v). Con-
Figure 5. SIRT1 opposes STAT3 acetylation in Lys685. A)
STAT3 acetylation in Lys685 was analyzed by Western blotting
performed on untreated or IL-22-activated keratinocytes. Blots
are representative of 3 independent experiments. B) STAT3
acetylation was also studied in keratinocytes transfected with
siRNAs specific for SIRT1 or SIRT7, and compared to NC.
Results are representative of 6 independent experiments.
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versely, basal keratinocytes of LS psoriasis exhibited a
reduced and less intense SIRT1 staining if compared to
healthy and NLS skin, especially at the tips of the epider-
mal papillae close to the CD3 T cell infiltrate (Fig. 7Biii,
vi). Since T cells infiltrating psoriatic lesions produce very
high amounts of IFN- (i.e., Th1, Th1/Th17 and T
cytotoxic cells), we hypothesized that SIRT1 decrement in
LS psoriatic keratinocytes could be due to local T-cell-
derived IFN-. Indeed, treatment of keratinocyte cultures
with supernatants obtained from Th1 clones releasing
high amounts of IFN- (25–35 ng/ml/106 cells) reduced
SIRT1 protein expression (Fig. 7C). Keratinocyte treat-
ments with recombinant cytokines typically present in
psoriatic skin confirmed that only recombinant IFN-,
and not TNF-, IL-17, or IL-22, could reduce SIRT1
mRNA and protein expression in human keratinocytes
(Fig. 7C). As a whole, these data demonstrate that al-
though SIRT1 is expressed at comparable levels in kera-
tinocytes from patients with psoriasis and healthy individ-
uals, it is down-regulated in psoriatic epidermis, likely as a
result of the local overexpression of IFN-.
IFN- up-regulates basal STAT3 acetylation, thus
reinforcing the IL-22-induced STAT3 phosphorylation
and downstream effects in keratinocytes
To see whether the reduced SIRT1 expression by IFN-
could result in an increase of STAT3 acetylation and,
thus, in enhanced STAT3 phosphorylation in response
to IL-22, we performed Western blotting experiments
on keratinocyte cultures prestimulated with IFN- or
TNF-, and then activated with IL-22. As shown in Fig. 8A,
IFN- significantly enhanced basal STAT3 acetylation
in Lys685 (lane 2 vs. 1) as well as the IL-22-induced
phosphorylation of STAT3 in Tyr705, as compared to
treatment with IL-22 alone (lane 5 vs. 4). The effect was
specific for IFN- since TNF- could not regulate
neither basal STAT3 acetylation (Fig. 8A, lane 3 vs. 1)
nor IL-22-induced STAT3 phosphorylation (Fig. 8A,
lane 6 vs. 4). Accordingly, SIRT1 silencing in keratino-
cytes further enhanced the IFN--induced acetylation
in Lys685 of STAT3 (Fig. 8A). Concomitantly to the
up-regulation of IL-22-induced STAT3 phosphoryla-
tion, IFN- strengthened IL-22-promoted downstream
effects. In particular, IFN- significantly enhanced IL-
22-induced expression of CXCL8, CXCL1, and SOCS3
mRNA (Fig. 8B), as well as IL-22-inhibited accumula-
tion of KRT1 (Fig. 8D). Interestingly, nuclear PCNA was
strongly reduced by IFN- (Fig. 8C), which notoriously
exerts an antiproliferative effect on keratinocytes (26).
DISCUSSION
Epidermal keratinocytes of psoriatic skin are character-
ized by activated STAT3, and increased levels of cyto-
Figure 6. Positive effects of
IL-22 on keratinocyte prolifer-
ation and migration are coun-
teracted by SIRT1. A) Prolifer-
ation of keratinocytes treated
with 10 M Ex-527 or 40 M
resveratrol either in presence
or absence of IL-22 was pro-
portional to crystal violet incor-
poration. Crystal violet assay was
also performed on keratino-
cytes transfected with SIRT1 or
irrelevant siRNA and treated
with IL-22. Crystal violet incor-
poration was measured with an
ELISA reader after 2 d of culture
and is expressed as fold induc-
tion of treated vs. untreated sam-
ples, which were given a value of
1. *P  0.05; **P  0.01. B) Scratch assays were carried out on keratinocytes silenced for STAT3 (STAT3si) or SIRT1 (SIRT1si)
or treated with irrelevant siRNA (NCsi), and incubated or not with 30 ng/ml IL-22 for 48 h. Residual gap between migrating
keratinocytes is expressed as percentage of initial scratched area. *P  0.01 vs. NCsi samples; **P  0.01 vs. IL-22-treated NCsi
samples.
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kines and growth factors that promote STAT3 activa-
tion have been found within psoriatic lesions (12, 27).
Among them, IL-22 potently triggers STAT3, which has
a pathogenetic role by altering the proliferative and
differentiation processes in keratinocytes, and inducing
inflammatory molecules (9). STAT3 proper activation
requires phosphorylation in Tyr705 and in Ser727
residues but also Lys685 acetylation (13, 28). Recently,
Nie et al. (16) have described the involvement of SIRT1
in promoting STAT3 Lys685 deacetylation, and, thus, in
down-regulating STAT3 phosphorylation and activity in
epatocytes during gluconeogenesis. STAT3 acetylation
is rarely found in resting cells but it can be efficiently
induced by cytokines, such as oncostatin M, IL-6, and by
type I IFNs (15). In this study, we showed that STAT3
acetylation in Lys685 is constitutive in human keratino-
cytes, and negatively controlled by SIRT1. STAT3 acet-
ylation in Lys685 was also found to be modulated by
IFN-, which strongly induced acetylated STAT3 by
repressing SIRT1 expression in keratinocytes. SIRT1
inhibition by IFN- was an event occurring also in vivo,
especially in skin diseases characterized by an infiltrate
of IFN--releasing T cells. For instance, psoriasis
showed a decrease of SIRT1 expression in basal layer
keratinocytes, especially at the tips of the epidermal
papillae close to the CD3 T-cell infiltrate. However,
the constitutive expression of SIRT1 was similar in
psoriatic and healthy cultured keratinocytes as well as
in healthy and NLS psoriatic skin, indicating that the
impaired SIRT1 expression was the consequence of the
microenviromental cytokine milieu and not an intrinsic
defect of the psoriatic epidermis. SIRT1 inhibition by
IFN- leading to the enhancement of Lys685 acetyla-
tion of STAT3 could represent a central molecular
event reinforcing keratinocyte responses to IL-22. In
fact, IFN- pretreatment of keratinocyte cultures
strongly enhanced STAT3 phosphorylation in Tyr705
and STAT3-dependent gene expression induced by
IL-22. The amplificatory effect of IFN- on IL-22 signal-
ing in keratinocytes is analogous to that promoted by
TNF-, even if the molecular mechanisms and genes
regulated by the combination of IL-22 and TNF- are
completely different (5). The specificity of IFN- and
TNF- effects on IL-22 signaling could depend on their
ability to regulate and activate different molecular
pathways. Concerning STAT3 signaling, TNF-, differ-
ently from IFN-, did not affect the phosphorylation of
STAT3 nor its acetylation. Other than potentiating
Figure 7. SIRT1 expression is down-regulated in
vivo in psoriasis lesions and in vitro by T-cell-derived
IFN-. A) Cultured keratinocytes were prepared
from healthy skin or from biopsies taken from
uninvolved (NLS KC) or involved (LS KC) psoriatic
skin. SIRT1 protein level was detected in total (top
panel) or fractionated (bottom panel) lysates of
keratinocytes; 3 of 6 representative psoriatic and
healthy keratinocyte strains are shown. B) Immu-
nohistochemistry for SIRT1 and CD3 (both stained
in red) was performed on frozen sections from
biopsies of psoriatic skin including LS (ii, v), and NLS (iii, vi) areas of plaques. Healthy skin was also analyzed (i, iv).
Immunoreactivity was revealed by using 3-amino-9-ethylcarbazole as substrate. Arrows (iii) indicate area of epidermal
papillae where SIRT1 staining was reduced. Representative stainings of 6 psoriatic sections analyzed are shown. C) Western
blotting of SIRT1 performed on keratinocyte cultures after 24 h activation with diluted (1:3) supernatants derived from 3
Th1 clones (AC1.36, FN2.26, and RS3.7) that produce high amounts of IFN- (25–35 ng/ml/106 cells). Th1 clones were
prepared from peripheral blood of patients with psoriasis; and supernatants were collected after 48 h activation with
anti-CD3 and anti-CD28. Alternatively, SIRT1 expression was analyzed by real-time PCR or Western blotting in samples
activated with recombinant IFN-, TNF-, IL-17 or IL-22 (right panel). Western blots are representative of 2 independent
experiments performed on 2 different keratinocyte strains. *P  0.01.
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IL-22 signaling in keratinocytes, IFN- was also able to
counteract IL-22-induced downstream effects in kera-
tinocytes. In fact, it could reduce both basal and
IL-22-promoted PCNA nuclear accumulation, accord-
ingly to its potent antiproliferative effect on this cell
type. Therefore, IFN- can either potentiate or inhibit
IL-22 signaling, with this dual effect depending on the
IFN- ability to induce, in addition to STAT3 acetyla-
tion, other molecular cascades. Among these, STAT1
activation, usually associated with a decrease in prolif-
eration rate in IFN--sensitive cells, could be responsi-
ble for the dominant inhibitory effect of IFN- on
IL-22-induced PCNA expression. It would be important
to evaluate whether IFN- has a prevailing role also on
IL-22-induced proliferation in keratinocytes, and
whether psoriatic keratinocytes are less or more sensi-
tive than healthy cells to the antiproliferative or mito-
genic effect of IFN- and IL-22, respectively. Indeed,
previous studies have already shown that psoriatic kera-
tinocytes aberrantly respond to IFN-, whose injection
into uninvolved psoriatic skin causes epidermal hyper-
plasia and plaque development (29). The enhanced
proliferative response of psoriatic keratinocytes to
IFN- has been supposed to rely on a reduced activa-
tion of STAT1 signaling and on an altered expression
level of the IFN- receptor complex in the epidermis of
psoriatic lesions compared to healthy skin (30).
The SIRT1 inhibitory effect on STAT3 acetylation in
Lys685 influenced only the IL-22-induced phosphoryla-
tion in Tyr705, and not in Ser727 of STAT3, as assessed by
silencing SIRT1 expression. In addition, SIRT1 could not
modulate IL-22-dependent ERK1/2 phosphorylation, in-
dicating the selectivity of SIRT1 action on STAT3. Indeed,
it is well known that SIRT1 can regulate the acetylation
status and, thus, the phosphorylation and function of
several transcription factors, including p53, E2F1, NF-B,
c-Jun, and members of the FoxO family (31). Modifica-
tion of STAT3 acetylation in keratinocytes by manipulat-
ing SIRT1 expression confirmed the fundamental role of
SIRT1 in regulating the IL-22-induced STAT3 activity. In
fact, while SIRT1 depletion enhanced STAT3 transacting
capability, its overexpression inhibited STAT3 function in
IL-22-treated keratinocytes. As a direct consequence of
enhanced STAT3 activity, SIRT1-depleted keratinocytes
were more sensitive than control cells to the effects of
IL-22, which could better induce CXCL8, CXCL1, and
SOCS3 mRNA expression as well as nuclear translocation
of PCNA, cyclin D1, and pRB. SIRT1-silencing and, thus,
STAT3 activity enhancement in keratinocytes also re-
sulted in an increased reduction of KRT1 and loricrin
Figure 8. IFN- up-regulates basal STAT3
acetylation and reinforces some IL-22-in-
duced effects in keratinocytes. A) Cultured
keratinocytes were pretreated for 24 h with
IFN- or TNF-, then stimulated with IL-22
for 30 min. Total lysates were analyzed by
Western blotting; amounts of acetyl STAT3
and phosphorylated STAT3 were analyzed by
densitometry. Analyses of acetyl STAT3 were also performed on keratinocytes transfected with irrelevant or SIRT1 siRNA and activated
for 24 h with IFN- or TNF-. B) CXCL8, CXCL1, and SOCS3 mRNA expression was evaluated by real-time PCR in cultured
keratinocytes treated with IL-22 and/or IFN-.C) Nuclear PCNA was analyzed in keratinocytes treated with IL-22 and/or IFN- for 24 h.
D) KRT1 expression analysis was performed on keratinocyte cultures undergoing terminal differentiation or stimulated with IL-22
and/or IFN- for 4 d. Variations of PCNA and KRT1 levels were also determined by densitometry. Western blots are representative of
2 independent experiments performed on 2 different keratinocyte strains. *P  0.05; **P  0.01.
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expression. In addition, SIRT1 influenced the IL-22-
induced biological effects on keratinocytes, since it could
significantly inhibit the mitogenic and migratory activities
of IL-22 in these cells. In particular, enzymatic activation
of SIRT1 by resveratrol and inhibition by Ex-527 could
reduce and enhance, respectively, the IL-22-induced ke-
ratinocyte proliferation. Also, SIRT1-silenced keratino-
cytes proliferated more actively in response to IL-22
compared to control cells, and showed enhanced IL-22-
induced wound healing. Since the IL-22-induced closure
of keratinocyte layer was strictly dependent on STAT3, it
is possible that the negative effects of SIRT1 on IL-22-
induced wound healing were explicated through the
inhibition of STAT3 acetylation. It would be interesting to
analyze whether, similarly to psoriasis, SIRT1 keratinocyte
expression is impaired during skin wound healing pro-
cesses. This hypothesis is in line with the observations that
keratinocytes of both psoriasis and cutaneous wound
healing sites are both oriented toward a robust regenera-
tive program in response to IL-22 and display a strong
STAT3 activation driving tissue regeneration and protec-
tion (5, 9). SIRT1 inhibitory function on proliferative
processes of keratinocytes is consistent with previous data
demonstrating that SIRT1 is an inhibitor of keratinocyte
proliferation and an inducer of keratinocyte differentia-
tion. SIRT1 inhibition of keratinocyte proliferation could
occur through a mechanism involving cell cycle regula-
tors, such as E2F1 (17). Therefore, the decrement of the
prodifferentiation activity by SIRT1 in psoriatic keratino-
cytes could be responsible for the altered phenotype of
psoriatic epidermis, which is characterized by a reduction
of the differentiated cell compartment with respect to the
germinative layer (32).
In this study, we showed that SIRT1 was constitutively
expressed by keratinocytes and efficiently contributed to
STAT3 deacetylation in these cells (Fig. 9). During inflam-
matory skin processes characterized by a concomitant
presence of IFN- and IL-22, IFN- strongly down-regu-
lated the keratinocyte expression of SIRT1 and IL-22
activated STAT3. SIRT1 decrement determined an accu-
mulation of STAT3 acetylated in Lys685, thus favoring
STAT3 phosphorylation in Tyr705 and keratinocyte re-
sponses to IL-22. Among molecules regulated by IL-22-
induced STAT3 and influenced by SIRT1, PCNA, cyclin
D1, and pRB play a fundamental role in proliferation, a
biological process robustly induced by IL-22 in keratino-
cytes during proliferative skin disorders, such as psoriasis.
In psoriatic lesions, SIRT1 inhibition could be responsible
for the strong activation of STAT3 and, thus, for the
exaggerated responses of epidermal keratinocytes to IL-22
and other proinflammatory cytokines signaling through
STAT3 (i.e., IL-6 and oncostatin M) (15, 33). Therefore,
the use of activators of SIRT1 decreasing STAT3 acetyla-
tion in epidermal keratinocytes may be therapeutically
relevant for the treatment of psoriasis but also for other
skin diseases characterized by aberrant STAT3 activation.
The latter include cutaneous tumors, such as papilloma
and squamous cell carcinoma, where STAT3 has a role in
the tumor promotion stage of epithelial carcinogenesis
(34). Indeed, STAT3 inhibition by STAT3 decoy oligonu-
cleotides in mice harboring activated STAT3 abrogated
the de novo generation of tape stripping-induced psoriatic
lesions in mice overexpressing STAT3 in the epidermis as
well as the development of TPA-induced skin carcinoma
(12, 27, 34). In addition, the STAT3 inhibitor STA-21
molecule, an antibiotic which blocks STAT3 dimerization
and DNA binding, has been successfully employed in a
pilot study for the treatment of psoriasis (35). Further
investigation will be required to unveil the effects of
SIRT1 and STAT3 interplay in keratinocytes, and mainly
the outcome of an efficient manipulation of SIRT1 activity
in the epidermis that will ultimately allow development of
novel therapies for STAT3-dependent skin disorders.
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